Saratoga Resources (SARA) Provides Operations and Financial Update

Saratoga Resources, Inc. (NYSE MKT: SARA; the “Company” or “Saratoga”) today provided an update on the status of previously announced operations for the remainder of 2012 as well as guidance with respect to certain anticipated year-end financial metrics.

With respect to the previously announced QQ-209 “Buddy” development well, Saratoga has contracted the Parker 50-B drilling rig, which is currently being mobilized to location, and plans to spud the well this Sunday, December 23. Drilling operations on the Buddy well are expected to be completed by year end.

With respect to the previously announced recompletion operations in Grand Bay Field, operations have been completed and the Company has released the Moncla 118 workover rig. Operations on the MP-47 SL 195 QQ-24 well in Grand Bay Field consisted of a gravel-pack completion of the 29M sand while setting up the 20 sand as a future non gravel-pack completion. The well is expected to be brought on production in the next week. On the GPLD A-191 well in Grand Bay Field, the Company performed diagnostic work and has set a retrievable plug to accommodate future operations pending evaluation of its alternatives to access the associated reserves.

The Company also announced that its projected full year 2012 Discretionary Cash Flow is estimated at $30 million, or approximately $1.00 per share, and that its projected year end cash balance is estimated to be in excess of $32 million.

Management Comments

Mr. Thomas F. Cooke, Chairman and Chief Executive Officer of Saratoga Resources, said, “We are pleased to announce that we have returned to executing our development plan with the recompletion of our MP-47 SL 195 QQ-24 well, which came in under budget and ahead of schedule, and the imminent spud of our QQ-209 “Buddy” development well. In addition, the diagnostics performed on our GPLD A-191 are expected to allow us to develop an appropriate plan to maximize production from the well. As we bring the year to a close, we have returned production to normal operating levels after the shut-ins caused by Hurricane Isaac and once more building cash flow and our cash position. While financial performance for the year and our financial position have been impacted by the effects of Hurricane Isaac, including deferral of production and associated revenues estimated to exceed $7 million and deferral of our development plan and associated production and revenues, we are pleased with these anticipated results, all of which indicate that we are generating positive cash flow from operations and are well positioned to effect our 2013 business plan.”

Non-GAAP Financial Measures

Discretionary Cash Flow and Discretionary Cash Flow Per Share are non-GAAP financial measures.

Discretionary Cash Flow and Discretionary Cash Flow Per Share are supplemental financial measures used by the company’s management and by securities analysts, investors, lenders, rating agencies and others who follow the industry as an indicator of the company’s ability to internally fund exploration and development activities. Discretionary cash flow should not be considered as a substitute for net income, operating income, cash flows from operating activities or any other measure of financial performance or liquidity presented in accordance with generally accepted accounting principles (“GAAP”). Discretionary cash flow excludes some, but not all, items that affect net income and operating income and these measures may vary among other companies. Therefore, the company’s Discretionary Cash Flow or its Discretionary Cash Flow Per Share may not be comparable to similarly titled measures used by other companies.

About Saratoga Resources

Saratoga Resources is an independent exploration and production company with offices in Houston, Texas and Covington, Louisiana. Principal holdings cover 32,119 gross/net acres, mostly held-by-production (all depths), currently located in the transitional coastline and protected in-bay environment on parish and state leases of south Louisiana. Most of the company’s large drilling inventory has multiple pay objectives that range from as shallow as 1,000 feet to the ultra-deep prospects below 20,000 feet in water depths of less than 10 feet. For more information, go to Saratoga’s website at www.saratogaresources.com and sign up for regular updates by clicking on the Updates button.

Forward-Looking Statements

This press release includes certain estimates and other forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “assumes”, “seeks”, “estimates”, “should”, and variations of these words and similar expressions, are intended to identify these forward-looking statements. While we believe these statements are accurate, forward-looking statements are inherently uncertain and we cannot assure you that these expectations will occur and our actual results may be significantly different. These statements by the Company and its management are based on estimates, projections, beliefs and assumptions of management and are not guarantees of future performance. Important factors that could cause actual results to differ from those in the forward-looking statements include the factors described in the “Risk Factors” section of the Company’s filings with the Securities and Exchange Commission. The Company disclaims any obligation to update or revise any forward-looking statement based on the occurrence of future events, the receipt of new information, or otherwise.

OCZ Technology (OCZ) Receives Extension to Regain Compliance With NASDAQ

SAN JOSE, CA–(Marketwire – December 20, 2012) – OCZ Technology Group, Inc. (NASDAQ: OCZ), a leading provider of high-performance solid-state drives (SSDs) for computing devices and systems, today announced that the Nasdaq Stock Market (“Nasdaq”) has accepted the Company’s plan to regain compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”) which will permit the continued listing of the Company’s stock on the Nasdaq Capital Markets.

On December 17, 2012, the Company submitted to Nasdaq a plan to regain compliance with the Rule. After reviewing the Company’s plan to regain compliance, Nasdaq granted an exception to enable the Company to regain compliance with the Rule. Under the terms of the exception, on or before February 28, 2013, the Company must file its 10-Q for the period ended August 31, 2012 and all other delinquent periodic reports, as required by the Rule.

About OCZ Technology Group, Inc.
Founded in 2002, San Jose, CA-based OCZ Technology Group, Inc. (OCZ) is a global leader in the design, manufacturing, and distribution of high-performance solid-state storage solutions and premium computer components. Offering a complete spectrum of solid-state drives (SSDs), OCZ provides SSDs in a variety of form factors and interfaces (i.e. PCIe, SAS and SATA) to address a wide range of client and enterprise applications. Having developed firmware and controller platforms, to virtualization and endurance extending technologies, the Company delivers vertically integrated solutions enabling transformational approaches to how digital data is captured, stored, accessed, analyzed and leveraged by customers. For more information, please visit: www.ocztechnology.com.

Forward Looking Statements
Certain statements in this release relate to future events and expectations and as such constitute forward-looking statements involving known and unknown factors that may cause actual results of OCZ Technology Group, Inc. to be different from those expressed or implied in the forward-looking statements. In this context, words such as “will,” “would,” “expect,” “anticipate,” “should” or other similar words and phrases often identify forward-looking statements made on behalf of OCZ. It is important to note that actual results of OCZ may differ materially from those described or implied in such forward-looking statements based on a number of factors and uncertainties, including, but not limited to, the risk that additional information may arise from the oversight of the Audit Committee; the risk that the process of preparing and auditing the financial statements or other subsequent events would require OCZ to make additional adjustments; the time and effort required to complete the restatement of the financial reports; the ramifications of OCZ’s potential inability to timely file required reports; including potential delisting of OCZ’s common stock on NASDAQ; the risk of litigation or governmental investigations or proceedings relating to such matters; the risk that OCZ may not be able to successfully negotiate an amendment to its credit facility; market acceptance of OCZ’s products and OCZ’s ability to continually develop enhanced products; adverse changes both in the general macro-economic environment as well as in the industries OCZ serves, including computer manufacturing, traditional and online retailers, information storage, internet search and content providers and computer system integrators; OCZ’s ability to efficiently manage material and inventory, including integrated circuit chip costs and freight costs; and OCZ’s ability to generate cash from operations, secure external funding for its operations and manage its liquidity needs. Other general economic, business and financing conditions and factors are described in more detail in “Item 1A — Risk Factors” in Part I in OCZ’s Annual Report on Form 10-K filed with the SEC on May 14, 2012, and statements made in other subsequent filings. The filing is available both at www.sec.gov as well as via OCZ’s website at www.ocztechnology.com. OCZ does not undertake to update its forward-looking statements.

All trademarks or brand names referred to herein are the property of their respective owners.

Investor Contact:
Bonnie Mott
Senior Manager of Investor Relations
(408) 440-3428
bmott@ocztechnology.com

Press Contact:
Scott Harlin
Director of Marketing Communications – Enterprise
(408) 733-8400
sharlin@ocztechnology.com

Sino-Global (SINO) Announces Establishment of A Wholly-owned Canadian Subsidiary

– New Subsidiary will Provide Services for Ships Loading Commodities at Canadian Ports and Delivering them to China –

BEIJING, Dec. 19, 2012 /PRNewswire/ —Sino-Global Shipping America, Ltd. (Nasdaq: SINO), a leading non-state-owned provider of shipping agency services operating primarily in China, today announced that it has established a new wholly-owned subsidiary, Sino-Global Shipping Canada Inc., to provide services for ships loading commodities at Canadian ports and delivering them to China.

Sino-Global Shipping Canada is already providing shipping services to Baosteel’s vessels in Canada. Baosteel, based in Shanghai, China, is the second largest steel producer in the world with huge demands for iron ore and other commodities.

Mr. Cao Lei, Sino-Global’s Chief Executive Officer, stated, “As we have noted in the past, Sino- Global Shipping America Ltd. has always sought to expand its geographical reach by developing relationships and activities worldwide. The new wholly-owned Canadian subsidiary is another step in establishing Sino-Global as the pre-eminent provider of shipping services worldwide. Canada is a country rich in natural resources and is a major shipper of such commodities throughout the world.  We anticipate that Sino-Global Shipping Canada will open up additional Canadian business opportunities that will result in incremental revenues and earnings.

About Sino-Global Shipping America, Ltd.

Registered in the United States in 2001 and operating primarily in mainland China, Sino-Global is a leading, non-state-owned provider of high-quality shipping agency services. With local branches in most of China’s main ports and contractual arrangements in all those where it does not have branch offices, Sino-Global is able to offer efficient, high-quality shipping agency services to shipping companies entering Chinese ports. With a subsidiary in Perth, Australia, where it has a contractual relationship with a local shipping agency, Sino-Global provides complete shipping agent services to companies involved in trades between Chinese and Australian ports. Sino-Global also cooperates with companies in Hong Kong, China, India, and South Africa to offer comprehensive shipping agent services to vessels going to and from some of the world’s busiest ports.

Sino-Global provides ship owners, operators and charters with comprehensive yet customized shipping agency services including intelligence, planning, real-time analysis and on-the-ground implementation and logistics support. Sino-Global has achieved both ISO9001 and UKAS certifications.

Forward Looking Statements

No statement made in this press release should be interpreted as an offer to purchase any security. Such an offer can only be made in accordance with the Securities Act of 1933, as amended, and applicable state securities laws. Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties as identified in Sino-Global’s filings with the Securities and Exchange Commission. Actual results, events or performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as the date hereof. Sino-Global undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

For More Information

For a more detailed review of Sino-Global, please refer to Sino-Global’s web site: www.sino-global.com

CONTACTS:

Smart Investors Spot Profitable Upside in Neptune’s (NEPT) Recovery Plan

LOS ANGELES, CA — (Marketwire) — 12/19/12 — Neptune Technologies & Bioresources, Inc. (NASDAQ: NEPT) has seen its stock fall 45% from its closing price on November 7th. On December 8th, Neptune suffered a tragedy, in which their manufacturing facility and inventory were completely destroyed in an explosion that also took the lives of 3 of their employees and injured several others. The tragic explosion has left the Company without manufacturing facilities and inventory of their flagship Neptune Krill Oil product. Neptune’s stock price has been falling since and the rate of decline has accelerated in the last few days. On November 26th, Neptune put out an action plan which management will use as a guideline for returning to normalized business. With the stock down significantly and the management fighting hard for the future of the Company the question investors find themselves asking is can Neptune recover?

Contrary to some recent positions, Neptune is anything but dead in the water. Investors should look at the business from today forward. If investors take an inventory, they will see that the Company has many valuable assets, plenty of cash on hand, two pharmaceutical subsidiaries, and a plan to move forward from the tragedy to rebuild an efficient, growing and profitable business. Neptune’s core business, krill oil neutraceuticals, is a growing business that has a large and growing market, growing 70% in 2012 by some estimates, and has been a profitable business segment for Neptune for the last three years.

Below are the key points from Neptune’s recently unveiled Action Plan:

1. Resuming its neutraceutical operations and certain levels of sales of its Neptune Krill Oil® products to customers in the short term;

2. Maintaining key customer relationships and market share, particularly until production of Neptune Krill Oil® products can reach pre-incident levels;

3. Reconstructing an operational plant using the expansion facility that was under completion and certain existing equipment in the expansion, which expansion and equipment do not appear to have suffered considerable damages from the incident;

4. Pursuing partnerships and/or arrangements with one or more strategic partners for the outsourcing of production for Neptune Krill Oil® products, both as an interim measure to ensure certain levels of production prior to its new plant being fully operational and as a longer-term strategy to diversify sources and means of production; and

5. Prudently managing its financial resources while continuing its product development and clinical trials, including defending its patents and intellectual property and supporting as planned the pharmaceutical development of its two subsidiaries, Acasti Pharma Inc. (“Acasti“) and NeuroBioPharm Inc. (“NeuroBio“), whose operations have not been interrupted as a result of the incident.

Looking at the Action Plan there are many details that need to be addressed to make it successful. The primary issue is how to serve their customer base, maintain market share and customers while the rebuilding is taking place. The rebuilding of the manufacturing facility is key. In a conversation with the management we asked the important question of not just how long, but what is actually in place? Neptune was in the process of expanding the Sherbrooke manufacturing facility when the accident occurred. The facility was about 8 weeks from coming on line. This first expansion was planned to be a doubling of the capacity of the plant from 150,000kg/year to 300,000kg/year. A second expansion was to take the plant to 500,000kg/year. The fact is that the production line of the first expansion was completed. What this new facility had was the back-end of the process in the manufacturing; this line was to be supplied by the existing front-end process, which is the extraction process. The front-end of the operation was destroyed. Neptune is on their way to building the new front-end processing, with machinery ordered and plenty of space available in the expansion facility. The back-end process equipment already in place is more sophisticated, costly and time consuming equipment, which gives the management confidence they can have the Sherbrooke plant back up and operational in the previously stated six months. The bottom line on the plant is that much of it is already in place.

Going back to the plan, items 1, 2, and 4 can be grouped together. This goes back to the question of how to serve the customer base and maintain market share and customers during the six months until Sherbrooke is operational. Management has been active in the development of potential manufacturing partners. These potential partners have been identified and management has engaged in discussions. Management’s job number one in these discussions is to find available capacity and supply their current customer base and fulfill the current orders. Due to fulfilling these orders on short notice through other suppliers, Neptune will be able to maintain their revenues, but the margins will be greatly reduced for at least two quarters. The important fact is Neptune should be able to continue its business with minimal issues for their customers until Sherbrooke is ready to go.

A benefit of this process is Neptune will have access to multiple suppliers of their formulation of Neptune Krill Oil (NKO). In the long run, not only will Neptune have the safety of supply diversification, but they will have the potential to outsource the majority of their manufacturing needs. Neptune will be able to focus on product development, intellectual property development, marketing and the pharmaceutical subsidiaries, while decreasing overall cost and expanding margins. These relationships may also make the next planned expansion of Sherbrooke to 500,000kg/year unnecessary, saving Neptune up to $5 million of dollars in capital expenditures (according to the October 3rd funding use of proceeds). At the very least these future partners will alleviate the need for further expansions beyond the 500,000kg/year planned expansion. In 2004 when Neptune began producing NKO, there were no producers from which to acquire outsourced product and Neptune had to build their own manufacturing facilities. Now, just over 8 years later, there are many manufacturers willing to go into krill oil manufacturing as krill oil has established a growing global market.

Item number 5 in the action plan has many facets. “Prudently managing its financial resources,” pretty much sums it up. On October 2nd Neptune announced the closing of a $34.1 million financing that was led by RBC Capital Markets and JMP Securities, two well-respected brokerage firms. The investors in the offering were primarily institutional investors. The current cash position per share is $0.70/share. This is a significant amount of cash to have on hand to bridge the six months until the manufacturing factory reopens. On top of that, the Company also has both property damage and business interruption insurance. In an article released by Reuters, André Godin, CFO of Neptune, stated that the factory was insured for about $20 million and the money would be used to optimize the existing expansion facility at Sherbrooke. Mr. Godin went on to say that the factory would come online in about six months. The business interruption insurance will provide some compensation to the company to help cover losses incurred from the immediate outsourcing needs. These two insurance policies will help limit the impact on the shareholders from this accident, to some extent.

Item five also discusses “continuing its product development and clinical trials, including defending its patents and intellectual property and supporting as planned the pharmaceutical development of its two subsidiaries, Acasti Pharma Inc. (‘Acasti‘) and NeuroBioPharm Inc. (‘NeuroBio‘).” These are important issues as it signifies it is still business as usual for the rest of the Company and its subsidiaries. These items mentioned are also valuation creators for Neptune, as all are important assets to the Company. A proper valuation analysis, which is not the purpose of this article, would show that the intellectual property of Neptune has substantial value, as the Company has successfully defended and proven the IP’s viability and worth in court several times against competitors’ claims.

More importantly, Acasti Parma Inc. just released interim data on its Phase II double blinded, placebo controlled clinical study for CaPre®. The data showed a statistically significant 25% (p < 0.05) reduction in triglycerides after eight weeks of treatment in 19 patients with baseline triglyceride levels between 204 and 476mg/dl. CaPre® also decreased Low Density Lipoprotein (LDL), Very Low Density Lipoprotein (VLDL) and non-HDL lipids and increased High Density Lipoprotein (HDL). This news increases the value of Acasti, and as a stand-alone it is possible that Acasti is worth more than the current market cap of Neptune.

The facts are simple; Neptune will have the Sherbrook up and running in about six months. The Company should be able to maintain supplies to customers and maintain revenues for a business segment that has been profitable for 3 years. Neptune has valuable assets; plenty of cash and the losses will be offset to some extent by insurance further preserving shareholder value. When the plant reopens, Neptune should be able to produce nearly as much in revenues as the September quarter. The Company will have new manufacturing partners, and there will be no constraints holding back Neptune from growing as much as their marketing efforts will allow. Acasti Pharma will be further along in its Phase II and preparing for its Phase III.

Shortly after Sherbrooke restarts, Neptune overall will be farther ahead as a business than they were when the accident occurred, with a more efficient structure. Neptune could also be more valuable if management executes on its plan. Some of the current institutional investors have acknowledged, for this article, that they are buyers of the stock at these levels and other are watching closely for potential entry points into the stock. Neptune had a market cap of around $250 million, and was growing, at the time the funding in October, and now the Company has a market cap of $100 million. We see a path for the Company to again produce at the sales and margin levels of the September quarter beginning in about six months, and it is possible for Neptune to reclaim its lost value over the course of the next 12 months. There is still some execution risk and the stock is speculative, but Neptune has too many assets not to further investigate the potential of investing in Neptune based upon the real facts of this Company. It is reasonable to conclude that the stock price can return to levels prior to the accident over the course of the next 12 months, which would be a very attractive potential ROI for investors from the previous closing price of $1.71/share.

The full report including charts and technical analysis is available at:

http://www.biomedreports.com/20121219117021/smart-investors-spot-clear-upside-in-neptunes-recovery-action-plan.html

Healthcare investors and Biotech traders interested in accessing BioMedReports’ new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to: http://biomedreports.com/fdacal.html

Follow Us

News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports

About BioMedReports.Com

BioMedReports is a news and research portal covering financial biotech news for the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. BioMedReports sells a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release are available at BioMedReports.Com

Add to Digg Bookmark with del.icio.us Add to Newsvine

Media Contacts Only:
M. Davila
Assistant Editor
BioMedReports.Com

Idera (IDRA) Announces Positive Top-line Results from Phase 2 Plaque Psoriasis Trial

Idera Pharmaceuticals Announces Positive Top-line Results from Phase 2 Trial of IMO-3100 in Patients with Moderate-to-Severe Plaque Psoriasis

Idera Pharmaceuticals (NASDAQ: IDRA) today announced that 48% of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in Psoriasis Area Severity Index (PASI) scores of 35% to 90% from baseline at the completion of a randomized, double-blind, placebo-controlled Phase 2a clinical trial of two dose levels of IMO-3100 administered for four weeks, with a four-week follow-up period. None of the 12 placebo-treated patients had improvement in this range; this difference was statistically significant (p<0.005). The Company believes the results of this trial provide clinical proof-of-concept for the mechanism of action of selective TLR inhibition in patients with psoriasis and potentially other autoimmune and inflammatory disorders.

“The clinical activity of IMO-3100 demonstrated in patients with moderate-to-severe plaque psoriasis is encouraging, especially given the short duration of treatment in this study that was designed for initial explorations of safety and efficacy,” commented Alexa Kimball, M.D., M.P.H., Vice Chair, Department of Dermatology at Massachusetts General Hospital, Boston, and an investigator in the trial.

“The achievement of statistically significant PASI reductions with only four weeks of treatment in a placebo-controlled double-blind trial directly supports the rationale that the modulation of specific TLRs plays a key role in the treatment of psoriasis and, potentially, other autoimmune and inflammatory disorders,” commented James Krueger, M.D., Ph.D., of The Rockefeller University, New York. “We are excited to see these data, which demonstrate the translation of targeting a novel mechanism of action into clinical activity and support further studies of TLR antagonists for the treatment of psoriasis. Our laboratory is continuing to evaluate the immunological pathways by which TLR antagonists suppress the signaling cascades that underlie psoriasis and have the potential to open up a new approach to disease treatment.”

About the IMO-3100 Phase 2 Trial in Psoriasis

The Phase 2 trial was a randomized, double-blind, placebo-controlled trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. In the trial, 44 patients were randomized to receive IMO-3100 monotherapy at 0.16 or 0.32 mg/kg or placebo by subcutaneous injection once weekly for four weeks with four weeks of follow-up. Assessments of safety were performed throughout the treatment and follow-up periods. Multiple parameters were monitored to assess the clinical activity of IMO-3100, including Psoriasis Area Severity Index (PASI), mean focal psoriasis severity and Physician Global Assessment (PGA) scores. In addition to the clinical assessments, biopsies of psoriasis plaques were evaluated for treatment-related changes in epidermal thickness and immune cell infiltrates consistent with the intended mechanism of action. Patients were enrolled at eleven sites in the United States.

Top-line clinical results from this trial include:

• Of the 44 enrolled patients, 40 were clinically evaluable at the end of the four-week treatment period and 37 were evaluable following the four-week follow up period
• Treatment at both IMO-3100 dose levels was well tolerated, with no treatment-related discontinuations
• Among evaluable patients, the median PASI scores at treatment initiation were 14.9, 16.1, and 12.5 in the 0.16 mg/kg, 0.32 mg/kg, and placebo cohorts, respectively
• A treatment effect was demonstrated in measures of clinical efficacy in patients in both IMO-3100 dose cohorts; PASI reductions at both dose levels were sustained throughout the four-week follow-up period
• At the end of the four-week follow-up period, 48% of patients treated with either dose of IMO-3100 (12 of 25) demonstrated improvements of 35% to 90% from baseline PASI scores compared with 0 of 12 in the placebo cohort; this difference was statistically significant (p<0.005)
• The trial achieved the pre-specified clinical endpoint of reduction in PASI scores at the end of treatment in the 0.16 mg/kg dose cohort with statistical significance (p<0.02) compared to the placebo cohort, but not in the 0.32 mg/kg dose cohort
• The 0.16 mg/kg cohort also achieved, with statistical significance (p<0.02), the pre-specified clinical endpoint of improvement in induration, a measure of plaque thickness, at the end of treatment and during the follow-up period
• At the end of the four-week follow-up period, 25% (3 of 12) of patients treated with 0.16 mg/kg dose and 31% (4 of 13) with 0.32 mg/kg dose achieved PASI 50 or greater, compared to 0 of 12 placebo patients

Skin biopsies were collected at baseline and after completion of treatment to investigate changes in epidermal thickness and immune cell infiltrates. Change in epidermal thickness was the primary endpoint for the trial. Placebo treated patients had a median change in epidermal thickness of +7.7% compared to a median change of -6.4% among IMO-3100 treated patients; this difference was not statistically significant. A known limitation of skin biopsies after four weeks of treatment is that psoriatic plaques do not resolve in a uniform fashion, and therefore, biopsies may not provide a representative sampling of lesions (ref: Ann Rheum Dis 2005;64:65-68).

The Company plans to present complete clinical data from this trial at an upcoming medical meeting.

“We believe this trial in patients with moderate-to-severe plaque psoriasis provides clinical proof-of-concept for this first-in-class TLR antagonist, which represents a novel approach to the treatment of autoimmune diseases. We are very pleased to have observed clinical responses after only four weeks of treatment,” stated Sudhir Agrawal, D. Phil., Chief Executive Officer of Idera. “The insights gained from this trial support expansion of our TLR antagonist program for the treatment of autoimmune diseases. In 2013, we plan to advance the clinical development of a selective TLR antagonist for the treatment of moderate-to-severe plaque psoriasis and also for the treatment of lupus.”

About TLRs and Idera’s Pipeline

Toll-like Receptors (TLRs) play a key role in inflammation and immunity. Of the 10 human TLRs identified to date, Idera is developing compounds targeted to TLRs 3, 7, 8 and 9, which are expressed in different cells and serve unique functions. Using its chemistry-based approach, Idera has created novel drug candidates that modulate immune responses through either activation or inhibition of specific TLRs. Inhibition of specific TLRs may be useful in treating autoimmune disorders, such as systemic lupus erythematosus (SLE), psoriasis and rheumatoid arthritis, by blocking the induction of multiple cytokines and signaling pathways. Idera’s clinical candidates for application in autoimmune diseases are IMO-3100, an antagonist of TLR7 and TLR9, and IMO-8400, an antagonist of TLRs 7, 8 and 9.

A characteristic of autoimmune diseases such as SLE and psoriasis is the production of immune complexes with self-nucleic acids. These abnormal immune complexes activate TLRs 7, 8 and 9 and induce multiple cytokines that cause further damage to the body’s own tissues and organs, thereby releasing more self-nucleic acids. Thus, a pathologic amplification cycle is established, promoting disease maintenance and progression. In preclinical models of several autoimmune diseases, IMO-3100 and IMO-8400 inhibited TLR-mediated immune responses, interrupted the cycle of disease maintenance and progression through decreases in Th1, Th17 and inflammasome pathways, and led to improvements in multiple measures of disease.

About IMO-3100

IMO-3100, an antagonist of TLR7 and TLR9, is a lead drug candidate in development to treat autoimmune diseases, including psoriasis. In preclinical mouse models of psoriasis, IMO-3100 exerted therapeutic activity by inhibiting disease-associated gene expression and cytokines, such as IL-6, IL-22, IL-17, IL-23, NLRP3 and IL-1β, and proteins in the skin such as S100A7, DEFB4 and LL37. In addition, histological evaluation showed that the psoriatic lesions in IMO-3100-treated animals had reduced epidermal thickness and decreased lymphocyte infiltration compared to control mice.

About Psoriasis

Psoriasis is a systemic immune-mediated disorder, characterized by inflammatory skin and joint manifestations. The most common form, plaque psoriasis, appears as raised, red patches covered with a silvery white buildup of dead skin cells. Psoriasis can occur on any part of the body and is associated with other serious health conditions, such as diabetes, heart disease and depression.

Psoriasis is the most prevalent autoimmune disease in the U.S., according to the National Psoriasis Foundation, affecting as many as 7.5 million Americans.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals applies its proprietary Toll-like receptor (TLR) drug discovery platform to create immunomodulatory drug candidates and has a clinical development program in autoimmune diseases. Additionally, Idera has a collaboration with Merck & Co. for the use of TLR-targeted candidates as vaccine adjuvants for cancer, infectious diseases and Alzheimer’s disease. The Company is also exploring its gene-silencing oligonucleotide (GSO) technology for the purpose of inhibiting the expression of disease-promoting genes. For more information, visit http://www.iderapharma.com.

Idera Forward Looking Statements

This press release contains forward-looking statements concerning Idera Pharmaceuticals, Inc. that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “should,” “could,” “will,” “may,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Idera’s actual results to differ materially from those indicated by such forward-looking statements, including whether Idera’s cash resources will be sufficient to fund the Company’s continuing operations and the further development of the Company’s autoimmune disease program; whether results obtained in preclinical studies and early clinical trials, such as the results from the Phase 2 trial and the preclinical studies referred to in this release, will be indicative of results obtained in future clinical trials; whether products based on Idera’s technology will advance into or through the clinical trial process on a timely basis or at all and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if the Company’s products receive approval, they will be successfully distributed and marketed; whether the Company will be able to license any of its TLR target candidates on a timely basis or at all; whether the Company’s collaboration with Merck & Co, Inc., will be successful; whether the patents and patent applications owned or licensed by the Company will protect the Company’s technology and prevent others from infringing it; and such other important factors as are set forth under the caption “Risk Factors” in Idera’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 which important factors are incorporated herein by reference. Idera disclaims any intention or obligation to update any forward-looking statements.

Dynatronics (DYNT) Announces Reverse Stock Split

SALT LAKE CITY, Dec. 19, 2012 /PRNewswire/ — Dynatronics Corporation (Nasdaq: DYNT) today announced that on December 17, 2012, at the Company’s annual meeting, the shareholders approved a one-for-five reverse stock split of the Company’s common stock.  Approximately 93% of the votes cast were in favor of the reverse split which becomes effective today.

“After careful analysis, our board of directors determined that the best course of action for shareholders was to maintain our Nasdaq listing where we have traded for the past 28 years,” stated Kelvyn H. Cullimore, Jr., chairman and president of Dynatronics.  “Our research showed that staying on Nasdaq provides greater liquidity through higher trading volumes, as well as tighter spreads between bid and ask prices, more market makers and overall better investor confidence compared to trading in the over-the-counter market as a result of being delisted from Nasdaq.”

The Company has a number of positive developments which management believes should bode well for the Company’s future performance.  “This week, we are completing the expansion of our California operation into a new, larger facility in Livermore, CA to better serve our west coast customers,” reported Cullimore.   “Beginning today, we will be operating from that new facility which will allow greater operating efficiencies than our previous facility.  In addition, our new SolarisPlus line of therapy devices is being well received by the market.  October was a very profitable month for the Company and should result in earnings for the quarter ended December 31^st improving significantly over the same period last year.”

The Company is also working on expanding its distribution channels over the coming quarters and will introduce a record number of new products in fiscal year 2013.  “We expect these expansion plans and new product introductions to lead us to higher profits in the coming year,” he added.

Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets. More information regarding Dynatronics is available at www.dynatronics.com.

This press release contains forward-looking statements. Those statements include references to the company’s expectations and similar statements such as the statement regarding expectations relating to share trading volume, operating efficiencies, future profitability, market acceptance of new products, and future operating results and growth. Actual results may vary from the views expressed in the forward-looking statements contained in this release. The development and sale of the company’s products are subject to a number of risks and uncertainties, including, but not limited to, changes in the regulatory environment, competitive factors, inventory risks due to shifts in market demand, market demand for the company’s products, availability of financing at cost-effective rates, and the risk factors listed from time to time in the company’s SEC reports.  The Company expressly disclaims any obligation or intention to update any forward-looking statement contained in this release.

ATSG (ATSG) Continues Fleet Modernization with Purchase of Three Boeing 757-200

Air Transport Services Group, Inc. (NASDAQ:ATSG) said today that its aircraft leasing subsidiary has reached agreement with National Air Cargo Group, Inc., for the purchase of three Boeing 757-200 aircraft that have been modified for combi (combined passenger and main-deck cargo) service.

ATSG said it anticipates that its subsidiary, Cargo Aircraft Management (CAM), will take delivery of one of the three 757 combi aircraft in December 2012, and the other two in early 2013.

Joe Hete, President and CEO of ATSG, said, “The purchase of these three 757 combis from National, plus the one 757 combi we already own, will complete our commitment to replace our four McDonnell-Douglas DC-8 combis with more modern fuel-efficient aircraft that better meet the requirements of our principal combi customer, the U.S. Military’s United States Transportation Command (USTRANSCOM). We look forward to providing USTRANSCOM with the improved operating performance and lower costs of the 757, as well as its greater passenger capacity. We are proud to be USTRANSCOM’s sole combi operator, serving primarily remote installations around the world that rely on the combi’s unique cargo and passenger transport capabilities.”

The 757 combis have a 34 percent lower fuel burn, ten more passenger seats and the same number of cargo pallet positions as the DC-8 combis they will replace. The combis will be owned by CAM and leased to and operated by ATSG’s airline subsidiary Air Transport International (ATI), under ATI’s contract with USTRANSCOM. Along with the three aircraft, CAM is also purchasing a spare 757-200 engine and some ancillary aircraft equipment from National.

As part of its fleet modernization program, prior to ATI’s latest combi contract award from USTRANSCOM that took effect in October 2012, CAM purchased a Boeing 757-200 for combi conversion. That aircraft is undergoing certification testing for the Federal Aviation Administration, and is due to complete that process and begin USTRANSCOM service early next year. All three of the National combis were designed and modified to meet or exceed the same FAA and USTRANSCOM requirements, including ETOPS (Extended-range Twin-engine Operational Performance Standards) certification essential for service to USTRANSCOM’s combi destinations.

Upon the retirements of the four DC-8 combis, ATSG’s fleet will consist entirely of 757-200, 767-200 and 767-300 aircraft, all of which require only two crew members, and which share a common pilot type rating.

“This purchase of the National 757 combi aircraft further enhances our position as the world’s largest independent provider of modern, fuel-efficient midsized cargo aircraft to customers around the world,” Hete said. “No other provider can match the flexibility we offer in midsized airlift, whether on a dry-lease, ACMI or charter basis.”

ATSG noted that, as a result of its decision to acquire one of the 757 combis in 2012, it has adjusted its previously disclosed guidance for aircraft-related capital expenditures in 2012 and 2013 to approximately $170 million and $95 million, respectively.

About ATSG

ATSG is a leading provider of aircraft leasing and air cargo transportation and related services to domestic and foreign air carriers and other companies that outsource their air cargo lift requirements. ATSG, through its leasing and airline subsidiaries, is the world’s largest owner and operator of converted Boeing 767 freighter aircraft. Through its principal subsidiaries, including three airlines with separate and distinct U.S. FAA Part 121 Air Carrier certificates, ATSG provides aircraft leasing, air cargo lift, aircraft maintenance services and airport ground services. ATSG’s subsidiaries include ABX Air, Inc.; Airborne Global Solutions, Inc.; Air Transport International, Inc.; Cargo Aircraft Management, Inc.; Capital Cargo International Airlines, Inc.; and Airborne Maintenance and Engineering Services, Inc. For more information, please see www.atsginc.com.

Except for historical information contained herein, the matters discussed in this release contain forward-looking statements that involve risks and uncertainties. There are a number of important factors that could cause Air Transport Services Group’s (“ATSG’s”) actual results to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the timely delivery by National Air Cargo Group to Cargo Aircraft Management (“CAM”) of the three Boeing 757-200 combi aircraft, , the timing associated with the completion of FAA certification testing for the Boeing 757-200 combi aircraft already owned by CAM, changes in market demand for our assets and services, and other factors that are contained from time to time in ATSG’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Readers should carefully review this release and should not place undue reliance on ATSG’s forward-looking statements. These forward-looking statements were based on information, plans and estimates as of the date of this release. ATSG undertakes no obligation to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes.

DS Healthcare (DSKX) to Ring NASDAQ Closing Bell

ADVISORY, Dec. 18, 2012 (GLOBE NEWSWIRE) —

What:

DS Healthcare Group, Inc. [DSKX], leader in the development of biotechnology for topical, and nutritional therapies, will visit the NASDAQ MarketSite in Times Square.

DS Healthcare Group, Inc., formerly Divine Skin Inc., began trading on the NASDAQ Capital Markets on December 13, 2012.

In honor of the occasion, Daniel Khesin, CEO, will ring the Closing Bell.

Where:

NASDAQ MarketSite – 4 Times Square – 43^rd & Broadway – Broadcast Studio

When:

Wednesday, December 19, 2012 – 3:45 p.m. to 4:00 p.m. ET

Contact:

Abner Silva
(407) 342-4112
abner@dslaboratories.com

NASDAQ MarketSite:

Jen Knapp
(212) 401-8916
Jennifer.knapp@nasdaqomx.com

Feed Information:
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Facebook and Twitter:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.

For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx.

Webcast:

A live webcast of the NASDAQ Closing Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx.

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About DS Healthcare Group, Inc. [DSKX]:

DS Healthcare Group, Inc. leads in the development of biotechnology for topical, and nutritional therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers and salons. Its brands include DS Laboratories (www.DSLaboratories.com), Sigma Skin (www.SigmaSkin.com), Polaris Research Laboratories (www.PolarisResearchLabs.com) and Pure Guild (www.ThePureGuild.com).

About NASDAQ OMX Group:

The inventor of the electronic exchange, The NASDAQ OMX Group, Inc., fuels economies and provides transformative technologies for the entire lifecycle of a trade – from risk management to trade to surveillance to clearing. In the U.S. and Europe, we own and operate 23 markets, 3 clearinghouses and 5 central securities depositories supporting equities, options, fixed income, derivatives, commodities, futures and structured products. Able to process more than 1 million messages per second at sub-40 microsecond speeds with 99.99+% uptime, our technology drives more than 70 marketplaces in 50 developed and emerging countries into the future, powering 1 in 10 of the world’s securities transactions. Our award-winning data products and worldwide indexes are the benchmarks in the financial industry. Home to approximately 3,400 listed companies worth $6 trillion in market cap whose innovations shape our world, we give the ideas of tomorrow access to capital today. Welcome to where the world takes a big leap forward, daily. Welcome to the NASDAQ OMX Century. To learn more, visit www.nasdaqomx.com. Follow us on Facebook (www.facebook.com/NASDAQ) and Twitter (www.twitter.com/nasdaqomx). (Symbol: NDAQ and member of S&P 500)

Vanda (VNDA) Announces Positive Phase III Results For Tasimelteon in Non-24-Hour Disorder

— Tasimelteon is shown to entrain the master body clock as measured by melatonin and cortisol circadian rhythms — Tasimelteon is shown to significantly improve clinical symptoms across a number of sleep and wake measures

WASHINGTON, Dec. 18, 2012 /PRNewswire/ — Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) today announced positive results from the SET (Safety and Efficacy of Tasimelteon) Phase III study, evaluating tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder (Non-24).  Tasimelteon succeeded in the primary endpoint of Entrainment of the melatonin (aMT6s) rhythm as compared to placebo.

Additionally, tasimelteon demonstrated significant improvements across a number of sleep and wake parameters including measures of total sleep time, nap duration, and timing of sleep.  Tasimelteon also showed significant improvements over placebo in the Non-24 Clinical Response Scale (N24CRS) as well as in the Clinical Global Impression of Change (CGI-C), an overall global functioning scale.  These results provide robust evidence of a direct and clinically meaningful benefit to patients with Non-24.

Non-24 is a serious, rare circadian rhythm disorder that affects a majority of totally blind individuals who lack light perception and cannot entrain (reset) their master body clock to the 24-hour day.  Currently there is no approved treatment for Non-24.

“Today’s results confirm tasimelteon as a strong circadian regulator capable of entraining the master body clock in patients with Non-24.  We are particularly impressed and excited by the magnitude and robustness of the direct clinical benefits to patients,” said Mihael H. Polymeropoulos, M.D., President and CEO of Vanda.  “We believe that tasimelteon can be an effective and clinically meaningful treatment for patients suffering with this debilitating disorder.”

“As a person who regularly experiences the debilitating symptoms of Non-24, these findings are important to me and I think they are important to the blind community as a whole, because they give us hope that a potential new treatment approach is on the horizon,” said Melanie Brunson, Executive Director of the American Council of the Blind.

Primary Endpoints

The SET study was an 84 patient randomized, double-masked, placebo-controlled study in patients with Non-24.  The primary endpoints for this study were Entrainment of the melatonin (aMT6s) rhythm to the 24-hour clock and Clinical Response as measured by Entrainment plus a score of greater than or equal to 3 on N24CRS.

Primary Endpoint Results

Table 1

Secondary Endpoints

The SET study also assessed a number of secondary endpoints including Entrainment of cortisol rhythm and a broad range of clinical sleep and wake parameters.  These parameters included improvement in the total nighttime sleep in the worst 25% of nights (LQ-nTST), decrease in the total daytime sleep duration in the worst 25% of days (UQ-dTSD) and midpoint of sleep timing (MoST) which is derived from a combination of the sleep reported for both nighttime and daytime.  CGI-C is a seven-point rating scale of global functioning with lower scores indicating larger improvements.

Secondary Endpoint Results

Table 2

The results of the SET study represent the initial data from the tasimelteon Non-24 Phase III development program and demonstrate the multiple benefits of this novel therapy in treating patients suffering from this rare circadian rhythm disorder.  In the SET study, tasimelteon was demonstrated to be safe and well tolerated.  Vanda expects to report top-line results from the second Phase III study (RESET) for tasimelteon in Non-24 in the first quarter of 2013.  Vanda plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in mid-2013.

“We would like to thank our patients, their advocates, investigators, advisors and colleagues for making this study possible,” said Mihael H. Polymeropoulos, M.D., President and CEO of Vanda.  “We look forward to the successful completion of the Non-24 clinical program.”

Non-24 Scale of Clinical Response (N24CRS)

Tasimelteon Development Program for Non-24

The SET study is the first of four clinical studies conducted as part of Vanda’s Phase III development program for tasimelteon in the treatment of Non-24.  Data from the RESET study, a Phase III study evaluating the maintenance of entrainment effect of tasimelteon, is expected in the first quarter of 2013.  In addition, two safety studies are ongoing to support an NDA filing in the U.S.  The tasimelteon Non-24 development program is the largest conducted to date for any investigational therapy for the treatment of Non-24.

About Non-24-Hour Disorder

Non-24-Hour Disorder (Non-24) is a serious, rare and chronic circadian rhythm disorder that affects a majority of totally blind individuals in the U.S., or between 65,000 and 95,000 people. Tasimelteon has been granted orphan drug designation for the treatment of Non-24 in both the U.S. and the European Union.  Non-24 occurs almost entirely in individuals who lack the light sensitivity necessary to entrain, or synchronize, the master body clock in the brain with the 24-hour day-night cycle.  Most people have a master body clock that naturally runs longer than 24-hours, and light is the primary environmental cue that resets it to 24-hours each day.  Non-24 sufferers have a master body clock that continually delays, putting them to sleep later and later each day, turning night into day and day into night, until the cycle starts all over again.  The sleep condition is highly disruptive, making it difficult to do well in school, hold down a job or maintain relationships.  For more information on Non-24, please visit http://24sleepwake.com/.

About Tasimelteon

Tasimelteon is a circadian regulator in development for the treatment of Non-24. Tasimelteon is a melatonin agonist of the human MT1 and MT2 receptors, with a 2-4 times greater specificity for MT2.  Tasimelteon’s ability to reset the master body clock in the suprachiasmatic nucleus (SCN), located in the hypothalamus, results in the entrainment of the body’s melatonin and cortisol rhythms to align to the 24-hour day-night cycle.  Tasimelteon is currently in development for both Non-24 and Major Depressive Disorder (MDD).

Conference Call
Vanda has scheduled a conference call for today, Tuesday, December 18, 2012 at 9 AM ET to discuss the trial results.  Investors can call 1-800-901-5231 (domestic) and 1-617-786-2961 (international) and use passcode 51793839.  A replay of the call will be available beginning Tuesday, December 18, 2012, at 11:00 AM ET and will be accessible until Tuesday, December 25, 2012, at 12:00 PM ET.  The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers.   The access number is 17591426.

The conference call will be broadcast simultaneously on Vanda’s website, http://www.vandapharma.com.  Investors should click on the Investor Relations tab and are advised to go to the website at least 15 minutes early to register, download and install any necessary software.   The call will also be archived on Vanda’s website for a period of 30 days, through January 17, 2013.

About Vanda Pharmaceuticals Inc.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda, please visit http://www.vandapharma.com.

Company Contact:
Jim Kelly
Senior Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com

Media Contact:
Kristie Kuhl
Senior Vice President
Makovsky & Company, Inc.
(212)-508-9642
kkuhl@makovsky.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Various statements in this release are “forward-looking statements” under the securities laws. Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “project,” “target,” “goal,” “likely,” “will,” “would,” and “could,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the company’s forward-looking statements include, among others: the inability to reach agreement with the FDA regarding Vanda’s regulatory approval strategy or proposed path to approval for tasimelteon for the treatment of Non-24-Hour Disorder; the failure of Vanda’s clinical trials to demonstrate the safety and/or efficacy of tasimelteon in the treatment of Non-24-Hour Disorder or Major Depressive Disorder; Vanda’s failure to obtain regulatory approval for tasimelteon for the treatment of Non-24-Hour Disorder or to comply with ongoing regulatory requirements; delays in the completion of Vanda’s RESET clinical trial for tasimelteon; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Vanda’s annual report on Form 10-K for the fiscal year ended December 31, 2011 which is on file with the SEC and available on the SEC’s website at www.sec.gov.  In addition to the risks described above and in Vanda’s annual report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda’s results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

PokerTek (PTEK) Re-Enters Mexico Gaming Market with PokerPro

MATTHEWS, N.C., Dec. 18, 2012 /PRNewswire/ — PokerTek, Inc. (NASDAQ: PTEK) announced today that it has re-entered the Mexico gaming market. Installations of PokerPro have commenced with games in several locations already live and in play.

“We are excited to see PokerPro back on the floor in Mexico, a market which previously represented over 17% of annualized recurring revenue,” commented Mark Roberson, Chief Executive Officer.

“Installations in Mexico will begin contributing incremental recurring revenue immediately, with 14 tables representing 140 gaming positions already in place and additional sites in planning for the rest of December and early 2013. Our re-entry into the Mexico market represents a significant catalyst for revenue growth and EPS profitability.”

About PokerTek, Inc.:

PokerTek, Inc. (NASDAQ:PTEK) is a licensed gaming company headquartered in Matthews, NC that develops and markets electronic table game solutions for the gaming industry. www.PokerTek.com

Contact:
Mark Roberson
CEO and CFO
PokerTek, Inc.
704.849.0860, x101
investorrelations@pokertek.com

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are made in accordance with the Private Securities Litigation Reform Act of 1995. Our actual results may differ materially from those implied in these forward-looking statements as a result of many factors, including, but not limited to, the impact of global macroeconomic and credit conditions on our business and the business of our suppliers and customers, overall industry environment, customer acceptance of our products, delay in the introduction of new products, further approvals of regulatory authorities, adverse court rulings, production and/or quality control problems, the denial, suspension or revocation of permits or licenses by regulatory or governmental authorities, termination or non-renewal of customer contracts, competitive pressures, and our financial condition, including our ability to maintain sufficient liquidity to operate our business. These and other risks and uncertainties are described in more detail in our most recent annual report on Form 10-K and other reports filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. We undertake no obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by applicable laws, and you are urged to review and consider disclosures that we make in the reports that we file with the Securities and Exchange Commission that discuss other factors germane to our business.

GlobalWise (GWIV) Announces Board Changes

COLUMBUS, OH — (Marketwire) — 12/18/12 — GlobalWise Investments, Inc. (OTCBB: GWIV) (OTCQB: GWIV) (www.GlobalWiseInvestments.com) and its wholly owned subsidiary Intellinetics, Inc., a leading-edge technology company focused on the design, implementation and management of cloud-based Enterprise Content Management (“ECM”) systems in both the public and private sectors, today announced the appointment of Mr. Roy H. Haddix to the Board of Directors of GlobalWise effective December 13, 2012, and the resignation of Ramon M. Shealy from the Board of Directors of GlobalWise effective December 17, 2012. Mr. Haddix has also been appointed to serve as Chairman of the Audit Committee of the Board, and as a member of the Nominating and Corporate Governance Committee of the Board. Mr. Shealy resigned for personal reasons and not as a result of any disagreements.

“We want to thank Mr. Shealy for his unselfish service, guidance and mentorship over the past several years,” stated William “BJ” Santiago, CEO of GlobalWise.

“We’re very pleased to announce that Roy has joined our Board of Directors,” continued Mr. Santiago. “2012 has been a year of significant growth in our channel partner program, client base and revenue. We believe Roy’s knowledge and experience will be of great value as we continue our efforts to rapidly scale our business and add new national and international channel partners in 2013.”

Roy H. Haddix is a senior operations, finance and accounting professional with over 30 years of experience. During his career, he has demonstrated leadership and developed fiscal policies for all levels of corporate organizations. Mr. Haddix has experience in the development of new accounting systems, processes and policies as well as working throughout organizations to increase efficiencies and reduce costs. Mr. Haddix began his accounting career operating and managing his own financial firm with over 700 clients from 1993 through 2001. From 2002 through 2006, Mr. Haddix served as Chief Financial Officer of Buffalo Construction, Inc. (BCI), a $50 million multi-state general contractor. During his tenure as part of the senior management team at BCI, he designed, implemented and managed strategic changes to financial, accounting and operational systems and procedures that enabled a 100% increase in sales while improving net income. From 2006 through 2008, Mr. Haddix was the Tax Manager at TMI, Inc., a $1.25 billion international manufacturing company and subsidiary of Toyota with responsibility for all domestic and international taxes. From 2010 through early 2012 Mr. Haddix served as Chief Financial Officer of Alpharion Capital Partners, Inc., a regional business development and venture capital firm focused on technology related ventures. Throughout his career Mr. Haddix has also been involved with numerous other entrepreneurial and philanthropic ventures.

About GlobalWise Investments, Inc.

GlobalWise Investments, Inc., via its wholly owned subsidiary Intellinetics, Inc., is a Columbus, Ohio based Enterprise Content Management (ECM) pioneer with industry-leading software that delivers cloud ECM based solutions on-demand. The Company’s flagship platform, Intellivue™, represents a new industry benchmark and game-changing solution by enabling clients to access and manage the content of every scanned document, file, spreadsheet, email, photo, audio file or video tape — virtually anything that can be digitized — in their enterprise from any PC, laptop, tablet or smartphone from anywhere in the world.

For additional information, please visit the Company’s corporate website: www.GlobalWiseInvestments.com

This press release may contain “forward-looking statements.” Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot predict the effect that market conditions, customer acceptance of products, regulatory issues, competitive factors, or other business circumstances and factors described in our filings with the Securities and Exchange Commission may have on our results. The company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.

GlobalWise Investments, Inc.
Columbus, Ohio
www.GlobalWiseInvestments.com
614-388-8909
Contact@GlobalWiseInvestments.com

Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975
Investors@MissionIR.com

Kandi’s (KNDI) First Batch of 300 EVs in Hangzhou City Passed Local DMV Inspection

DragonWave (DRWI) to Announce Third Quarter Fiscal Year 2013 Results

OTTAWA, ONTARIO — (Marketwire) — 12/17/12 — DragonWave Inc. (TSX:DWI)(NASDAQ:DRWI) a leading global supplier of packet microwave radio systems for mobile and access networks, today announced that it will report its third quarter fiscal year 2013 results after the close of markets in North America on January 9, 2013. The company will discuss the results on a conference call and webcast on January 10, 2013 beginning at 8:30 a.m. Eastern Time.

Webcast and Conference Call Details:

Toll-free North America Dial-in: (877) 312-9202

International Dial-in: (408) 774-4000

The live webcast and presentation slides will be available at http://investor.dragonwaveinc.com/events.cfm.

An archive of the webcast will be available at the same link.

About DragonWave

DragonWave® is a leading provider of high-capacity packet microwave solutions that drive next-generation IP networks. DragonWave’s carrier-grade point-to-point packet microwave systems transmit broadband voice, video and data, enabling service providers, government agencies, enterprises and other organizations to meet their increasing bandwidth requirements rapidly and affordably. The principal application of DragonWave’s products is wireless network backhaul. Additional solutions include leased line replacement, last mile fiber extension and enterprise networks. DragonWave’s corporate headquarters is located in Ottawa, Ontario, with sales locations in Europe, Asia, the Middle East and North America. For more information, visit http://www.dragonwaveinc.com.

DragonWave® and Horizon® are registered trademarks of DragonWave Inc.

Forward-Looking Statements

Certain statements in this release constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements as to DragonWave’s growth opportunities and the potential benefits of, and demand for, DragonWave’s products. These statements are subject to certain assumptions, risks and uncertainties, including our view of the relative position of DragonWave’s products compared to competitive offerings in the industry. Readers are cautioned not to place undue reliance on such statements. DragonWave’s actual results, performance, achievements and developments may differ materially from the results, performance, achievements or developments expressed or implied by such statements. Risk factors that may cause the actual results, performance, achievements or developments of DragonWave to differ materially from the results, performance, achievements or developments expressed or implied by such statements can be found in the public documents filed by DragonWave with U.S. and Canadian securities regulatory authorities. DragonWave assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Contacts:
Nadine Kittle
Marketing Communications
DragonWave Inc.
nkittle@dragonwaveinc.com
613-599-9991 ext 2262

John Lawlor
VP Investor Relations
DragonWave Inc.
jlawlor@dragonwaveinc.com
613-895-7000

Becky Obbema
Interprose Public Relations
(for DragonWave)
Becky.Obbema@interprosepr.com

Metalico (MEA) Enhances Footprint In Cleveland, Rochester

CRANFORD, NJ, December 17, 2012 – Metalico, Inc. (NYSE MKT: MEA) has increased its scrap metal recycling presence in northeastern Ohio and Western New York with a new venture in the Cleveland market and an acquisition in the Greater Rochester area.

In Cleveland, the Company has set up operations in a joint venture at 3018 East 55th Street, the site of a previous scrap yard in the city’s traditional industrial sector.  Managed by industry veteran Joseph Immormino, the strategically located facility, operating as “Metalico JBI Cleveland,” is expected to develop a brisk scrap peddler flow and to service new accounts while supporting Metalico’s existing yards in Akron and Youngstown.

The Company’s Metalico Rochester, Inc. subsidiary has purchased the assets of Bergen Auto Recycling, LLC, including its junk car inventory and real property located at 7652 Clinton Street Road in suburban Bergen, New York.  Metalico plans to significantly expand Bergen Auto’s salvage car buying capabilities and continue its “pick-and-pull” auto parts business while taking advantage of additional access to scrap metal to feed its shredding facility in Buffalo, New York.

Terms and consideration for the two transactions were not disclosed.

“These additions to our network should have an immediate benefit for us,” said Carlos E. Agüero, Metalico’s President and Chief Executive Officer.  “Our full-service scrap yard platforms are already well established in both of these geographic regions and have ample processing capacity to handle additional flow.  Our expansion into these new locations is consistent with Metalico’s growth strategy of penetrating geographically contiguous markets and benefiting from intercompany and operating synergies that are available through consolidation.”

Metalico, Inc. is a holding company with operations in three principal business segments: Ferrous and Non-Ferrous Scrap Metal Recycling, PGM and Minor Metals Recycling, and Fabrication of Lead-Based Products.  The Company operates 29 recycling facilities in New York, Pennsylvania, Ohio, West Virginia, New Jersey, Texas, and Mississippi and four lead fabricating plants in Alabama, Illinois, and California.  Metalico’s common stock is traded on the NYSE MKT under the symbol MEA.

Contact:
Metalico, Inc.
Carlos E. Agüero
Michael J. Drury
info@metalico.com

186 North Avenue East
Cranford, NJ 07016
(908) 497-9610
Fax:  (908) 497-1097
www.metalico.com

Velti (VELT) Shares Up On Jeff Ross Chief Financial Officer Appointment

Velti (NASDAQ: VELT), the leading global provider of mobile marketing and advertising technology and solutions, today announced the appointment of Jeff Ross as the company’s Chief Financial Officer, effective Monday January 7, 2013. With more than 25 years of international finance experience, including at Sybase and PricewaterhouseCoopers, Ross is the fourth senior executive to join Velti’s top ranks in the past six months.

Ross joins Velti from Sybase, where he has been Chief Financial Officer since 2007 and was before Chief Accounting Officer and Corporate Controller, until a $6.8 billion acquisition by SAP. He was responsible for developing, communicating, and monitoring all financial aspects of the company’s overall strategic plan, including controlling, financial planning and analysis, corporate development, tax, treasury, and investor relations. Prior to his promotion to Chief Financial Officer, Ross was Chief Accounting Officer and Corporate Controller of Sybase.

“Jeff is a highly accomplished and respected financial executive in the technology industry and, we are thrilled to have him join our team,” said Alex Moukas, Velti Chief Executive Officer. “His track record of providing strategic leadership and driving balanced growth and cash generation will help us further Velti’s position as the leader in mobile marketing and advertising technology for brands and advertisers. Jeff will lead the initiatives we have already commenced reviewing our organization and customer base, remaining focused on cash generation, ongoing reduction of operating and capital expenses and growth in our key markets.”

“With the recent additions of Jeff as CFO, Harry Patz as Chief Revenue Officer, Jason Hoffman as SVP Product Management and Jesper Helt as SVP Human Resources, we are well positioned as we start the next stage of our development” added Moukas.

“Velti is playing a leading role in helping to shape the rapidly evolving mobile marketing and advertising industry, and is uniquely positioned with its extensive global presence and potential,” said Ross. “I am very excited to join the Velti team and lead the company’s financial operations, with a focus on cash flow generation and growth in key markets.”

Wilson Cheung, Velti’s current Chief Financial Officer, will remain with Velti and transition into a new role in its fast-growing Asian markets. “As we welcome Jeff to Velti, we also want to thank Wilson for all of the effort that he provided in the last 3 years,” said Moukas. “We look forward to his continued contributions and thank him for his commitment to a smooth transition to Jeff,” concluded Moukas.

GenVec (GNVC) Single Administration of Vaccine Provides Protective Immunity Against HSV

Single Administration of GenVec’s Vaccine Provides Protective Immunity Against HSV in Pre-clinical Animal Models

GAITHERSBURG, Md., Dec. 17, 2012 /PRNewswire/ — GenVec, Inc. (NASDAQ:GNVC) announced today that data were presented on its HSV vaccine program at the Keystone Symposia meeting on Immunological Mechanisms of Vaccination, which is taking place in Ottawa, Ontario from December 13 to December 18, 2012.

The company disclosed that a single administration of its genetic vaccine was effective against HSV2 in two industry-accepted HSV disease models.  Specifically, immunization was shown to reduce viral shedding, and the recurrence and severity of lesions.

GenVec’s HSV vaccine candidate generated effective immune responses in animal models; and is composed of two novel antigens, as well as a proprietary, non-human adenoviral vector.

“We have substantial evidence that HSV infection can be controlled by inducing an appropriate T-cell response,” said Dr. Lisa Wei, Senior Director of Research and head of GenVec’s HSV program. “The data presented at this symposium demonstrate the progress we are making towards the goal of creating a vaccine for treatment and potentially prophylaxis of HSV infection.”

Research reported in this release was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under grant number 5R43AIO77147-02. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About Herpes Simplex Virus (HSV)

In the United States, approximately 40 million people are currently infected with HSV2, which is  responsible for most cases of genital herpes, and 1.6 million new infections occur each year. About 25% of those infected with the virus suffer clinical symptoms. Even higher infection rates are evident in developing countries. HSV2 infection is associated with increased HIV infection and transmission; and further complications of HSV are also often seen in those co-infected with HIV. HSV infections are permanent, and result in periodic virus shedding. Although antiviral regimens have become a standard of care, their inconvenience, cumulative cost and potential for drug resistance further underscore the need for safe, new approaches to reduce HSV lesions, virus shedding, and transmission. Estimated costs of treating HSV in the United States alone are close to $1 billion, primarily for drugs and outpatient medical care. There is no FDA-approved vaccine for HSV.

About GenVec

GenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec’s development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at www.genvec.com and in the Company’s filings with the U.S. Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding funding, grants, collaborations, revenues, cash burn rates, the development of products and the success of the Company’s collaborations, including with Novartis and Merial, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.  GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec’s product candidates under development; uncertainties relating to research and development activities; risks relating to the commercialization, if any, of GenVec’s proposed product candidates; dependence on the efforts of collaborators and third parties; dependence on intellectual property; currently unanticipated expenses, and risks that we may lack the financial resources and access to capital to fund our operations.  Further information on the factors and risks that could affect GenVec’s business, financial conditions and results of operations, are contained in GenVec’s filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.  These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.

Wireless Ronin (RNIN) Completion of One-for-Five Reverse Stock Split

MINNEAPOLIS, MN — (Marketwire) — 12/17/12 — Wireless Ronin Technologies, Inc. (NASDAQ: RNIN) today announced that its one-for-five reverse stock split was completed effective on the close of business on December 14, 2012. Trading of the Company’s common stock on The NASDAQ Capital Market will begin on a split-adjusted basis at the open of trading on December 17, 2012.

On November 29, 2012, the Company’s Board of Directors approved a one-for-five share combination of its common stock, also known as a reverse stock split, to be effective at 5:00 p.m. ET on December 14, 2012. The Company filed an amendment to its Articles of Incorporation to effect the reverse stock split.

The reverse stock split is intended to enable the per share trading price of the Company’s common stock to increase to satisfy the minimum bid price requirement for continued listing set forth in NASDAQ Listing Rule 5810(b).

As a result of the reverse stock split, every five shares of the Company’s common stock that were issued and outstanding as of the effective time were automatically combined into one issued and outstanding share without any change in the par value of such shares, and the number of authorized but unissued shares of the Company’s common stock was proportionally reduced. A proportionate adjustment also was made to the Company’s outstanding derivative securities. To reflect the reverse stock split, NASDAQ will append the fifth character “D” to the ticker symbol of the Company’s common stock for 20 business days.

No fractional shares of common stock will be issued as a result of the reverse stock split. Shareholders of record who would otherwise be entitled to fractional shares will receive cash in lieu of fractional shares.

Following the reverse stock split, the Company expects to have approximately 4,998,014 shares of common stock outstanding. The CUSIP number for the post-split shares will be 97652A 302.

About Wireless Ronin Technologies, Inc.
Wireless Ronin Technologies, Inc. (WRT) (NASDAQ: RNIN) (www.wirelessronin.com), is a marketing technologies company with leading expertise in current and emerging digital media solutions, including signage, interactive kiosks, mobile, social media and web, that enable clients to transform how they engage with their customers. WRT provides marketing technology solutions and services to clients, helping increase revenue and improve operating efficiencies to execute marketing initiatives. Since launching RoninCast® digital signage software in 2003, WRT has led the digital signage industry by bringing leading edge technology, services and support to its clients. WRT offers an array of services to support its clients’ marketing technology needs including consulting, creative development, project management, installation, training, and support and hosting. The company’s common stock trades on the NASDAQ Capital Market under the symbol “RNIN.” Follow us on Twitter (https://twitter.com/wirelessronin) and Pinterest (http://pinterest.com/rnin/) and like us on Facebook (https://www.facebook.com/wirelessronin).

Forward-Looking Statements
This release contains certain forward-looking statements of expected future developments, as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management’s expectations regarding continued listing on NASDAQ and other matters and are based on currently available data; however, actual results are subject to future risks and uncertainties, which could materially affect actual performance. Risks and uncertainties that could affect such performance include, but are not limited to, the following: estimates of future expenses, revenue and profitability; the pace at which the company completes installations and recognizes revenue; trends affecting financial condition and results of operations; ability to convert proposals into customer orders; the ability of customers to pay for products and services; the revenue recognition impact of changing customer requirements; customer cancellations; the availability and terms of additional capital; ability to develop new products; dependence on key suppliers, manufacturers and strategic partners; industry trends and the competitive environment; and the impact of losing one or more senior executives or failing to attract additional key personnel. These and other risk factors are discussed in detail in the risk factors section of the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 21, 2012.

Company Contact:
Darin P. McAreavey
Senior Vice President and Chief Financial Officer
Email Contact
952-564-3525

Investor Relations Contact:
Matt Glover or Michael Koehler
Liolios Group, Inc.
Email Contact

GreenHunter (GRH) Launches Modular Above-Ground Water Storage System

Proprietary MAG Tank™ Design Employs Patent Pending Standardized Interlocking Steel Panels Allowing Oil and Gas Operators to Customize Tank Footprint and Capacity

GreenHunter Energy, Inc. (NYSE MKT: GRH) (NYSE MKT: GRH.PRC), a diversified water resource, waste management and environmental services company specializing in the unconventional oil and natural gas shale resource plays, announced today that its wholly owned subsidiary, GreenHunter Water, LLC, has released its next-generation modular above-ground water storage tank system for general availability to the oil and gas industry. The fabrication of panels for the first MAG Tank unit has been completed with deployment slated for the last week in December in St. Mary Parish, Louisiana.

The Patent Pending MAG Tank™ design provides operators with a customizable steel tank footprint in unlimited capacity and shape configurations above 10,900 barrels. The MAG Tank™ is GreenHunter Water’s response to requests from our existing customers for a large capacity temporary water storage system that can be installed on a variety of well pads – especially those in challenging terrain as found in the states of Ohio, West Virginia, Pennsylvania and Kentucky in the Appalachian region. MAG Tank is an innovative substitute to the industry-standard circular above ground tank systems.

The MAG Tank™ significantly reduces truck traffic and environmental disturbance when compared to traditional frac tank and earthen impoundment alternatives. The tank’s robust steel standard panel wall units enable quick assembly and disassembly and a disposable impermeable liner and geotextile substrate provide fluid containment and a puncture resistant ground covering. After pad site preparation, a MAG Tank is typically installed in one to two days. The MAG Tank design exceeds current safety and engineering standards.

MANAGEMENT COMMENTS

Commenting on this new product line, Mr. Jonathan D. Hoopes, GreenHunter Energy’s President and COO, stated, “For oil and gas operators who are looking to reduce their cost, minimize truck traffic, increase safety, improve logistics and reduce environmental impact, the MAG Tank System is the solution. We have worked extremely hard over the past year to design a product that met all the requirements of our customers and at a manufacturing cost that insures our margin objectives. We are anxious to offer this uniquely designed system to our oilfield customers and anticipate this product to be significantly accretive to our projected earnings in fiscal 2013.”

About GreenHunter Water, LLC (a wholly owned subsidiary of GreenHunter Energy, Inc.)

GreenHunter Water, LLC provides Total Water Management Solutions™ in the oilfield. An understanding that there is no single solution to E&P fluids management shapes GreenHunter’s technology-agnostic approach to services. In addition to licensing of and joint ventures with manufacturers of mobile water treatment systems (Frac-Cycle™), GreenHunter Water is expanding capacity of salt water disposal facilities, next-generation modular above-ground storage tanks (MAG Tank™), advanced hauling and fresh water logistics services—including 21st Century tracking technologies (RAMCAT™) that allow Shale producers to optimize the efficiency of their water resource management and planning while complying with emerging regulations and reducing cost.

Additional information about GreenHunter Water may be found at www.GreenHunterWater.com.

Forward-Looking Statements

Any statements in this press release about future expectations and prospects for GreenHunter Energy and its business and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will,” “could,” “should,” “budget,” “continue,” and similar expressions constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in the press release include, without limitation forecasts of growth, revenues, adjusted EBITDA and SWD well and rolling stock expansion. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the substantial capital expenditures required to fund its operations, the ability of the Company to fund and implement its business plan, government regulation and competition. Additional risks and uncertainties are set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011, as well as the Company’s other reports filed with the United States Securities and Exchange Commission and are available at http://www.sec.gov/ as well as the Company’s website at http://greenhunterenergy.com/. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. All forward-looking statements are qualified in their entirety by this cautionary statement. GreenHunter Energy undertakes no obligation to update these forward-looking statements in the future.

Intelligent Systems (INS) Announces Third Quarter 2012 Results

Restates Prior Year to Conform to Current Accounting Standard

NORCROSS, Ga., Nov. 14, 2012 (GLOBE NEWSWIRE) — Intelligent Systems Corporation (NYSE Amex:INS) (www.intelsys.com) announced today its financial results for the three and nine month periods ended September 30, 2012. The comparative results for the 2011 periods have been restated to correct a misinterpretation of an accounting standard related to allocation of income/losses of noncontrolling common stock interests in a subsidiary, as explained in more detail below under the heading Restatement of 2011 Results.

For the three month period ended September 30, 2012, Intelligent Systems reported total revenue of $4,075,000 compared to $4,930,000 in the same quarter of 2011. The net income attributable to Intelligent Systems was $230,000 ($0.03 per basic and diluted share) compared to net income attributable to Intelligent Systems of $567,000 ($0.06 per basic and diluted share) in the third quarter of 2011.

For the nine month period ended September 30, 2012, total revenue was $12,201,000 compared to revenue of $12,631,000 in the comparable period of 2011. Net income attributable to Intelligent Systems was $225,000 ($0.03 per basic and diluted share) in the nine month period ended September 30, 2012 compared to net income of $1,158,000 ($0.13 per basic and diluted share) in the comparable period in 2011.

The year-to-date results are not directly comparable to prior year results due to non-recurring income of $450,000 that is included as Other Income in the year-to-date period ended September 30, 2011. As previously reported, the Company’s ChemFree subsidiary entered into a settlement agreement in May 2011 related to previously imposed court sanctions against a third party. The matter was resolved in ChemFree’s favor by payment to ChemFree of $450,000 for reimbursement of certain legal expenses.

J. Leland Strange, President and Chief Executive Officer, stated, “Our ChemFree subsidiary had another strong, profitable quarter, with revenue growth of nine percent in both the third quarter and year-to-date periods, compared to the same periods in 2011. The results were fueled by stronger sales and lease revenue from ChemFree’s SmartWasher® bio-remediating parts washers in the domestic U.S. market.

“Our CoreCard subsidiary results were consistent with those reported for the first two quarters of 2012. Revenue from professional services and maintenance activities increased in both the quarter and year-to-date periods of 2012 compared to the same periods in 2011. However, license revenue from new software contracts (which is classified as product revenue in our income statement) was lower in both the quarter and year-to-date periods of 2012 than in the same periods in 2011. We continue to invest substantial resources to develop our processing services business and enhance our financial transaction software solutions for prepaid, fleet and private label cards, which has had a major impact on our reported financial results.”

As we have frequently cautioned, results may vary from quarter-to-quarter due in part to the timing of CoreCard software contract revenue recognition. Generally, we defer all revenue associated with contract milestone payments on new CoreCard customer implementations until the contract is completed, which may frequently be affected by factors outside of our control.

Restatement of 2011 Results. On November 8, 2012, the Company determined that it had misinterpreted an accounting standard adopted in 2009 related to allocation of income/losses of noncontrolling common stock interests in a subsidiary. We have not been applying the guidance correctly in all respects because we have not been attributing to the noncontrolling interest (held by common shareholders of our CoreCord Software subsidiary) its share of the losses or income of the subsidiary and have not been disclosing such attributed amounts on the face of the consolidated statements of operations. Accordingly, we have restated the consolidated statements of operations for the quarter and year-to-date periods ended September 30, 2011 and the stockholders’ equity section of the consolidated balance sheets as of December 31, 2011 to comply with the standard. The restated prior year results now show on the face of the statement of operations, below the previously reported net income/loss figure, the allocation of net income/loss attributable to the noncontrolling interest and to Intelligent Systems Corporation and also the revised equity component of the balance sheet to reflect the allocation of cumulative losses to the noncontrolling interest. The restatement did not change the previously reported revenue, costs, expenses, net income/loss, cash flow, assets, liabilities or total shareholders’ equity. Earnings per share changed from the previously reported numbers (declining by $0.02 per share and increasing by $0.02 for the three and nine month periods ended September 30, 2011, respectively) because earnings per share is now calculated on net income/loss allocable to Intelligent Systems, rather than total net income/loss. Also, after restatement, shareholders’ equity attributable to Intelligent Systems at December 31, 2011 increased to $7,150,000 as compared to $5,531,000 previously reported and the noncontrolling shareholders’ equity interest became a deficit of $103,000 compared to equity of $1,516,000 as previously reported. Total stockholders’ equity was unchanged at $7,047,000.

The Company is filing a Form 8-K today with further details about the restatement of prior period financial statements and will file its Form 10-Q for the quarter ended September 30, 2012 as scheduled today, including the restated amounts and explanation thereof.

About Intelligent Systems Corporation

For over thirty years, Intelligent Systems Corporation has identified, created, operated and grown early stage technology companies. The Company has operations and investments in the information technology and industrial products industries. The Company’s principal majority-owned subsidiaries are CoreCard Software, Inc. (www.corecard.com), a provider of licensed software for managing accounts receivables, prepaid cards, private label revolving credit, debit and credit cards, fleet cards, consumer loans as well as processing services and ChemFree Corporation (www.chemfree.com), a leader in bioremediating parts washer equipment and supplies. Further information is available on our website at www.intelsys.com or by calling us at 770-381-2900.

In addition to historical information, this news release may contain forward-looking statements relating to Intelligent Systems Corporation and its subsidiary and affiliated companies. These statements include all statements that are not statements of historical fact regarding the intent, belief or expectations of Intelligent Systems Corporation and its management with respect to, among other things, results of operations, product plans, and financial condition. The words “may,” “will,” “anticipate,” “believe,” “intend,” “expect,” “estimate,” “plan,” “strategy” and similar expressions are intended to identify forward-looking statements. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. The Company does not undertake to update or revise any forward-looking statements whether as a result of new developments or otherwise, except as required by law. Among the factors that could cause actual results to differ materially from those indicated by such forward-looking statements are instability in the financial markets, delays in product development, undetected software errors, competitive pressures, changes in customers’ requirements or financial condition, market acceptance of products and services, changes in the performance, financial condition or valuation of affiliate companies, the risks associated with investments in privately-held early stage companies and further declines in general economic and financial market conditions, particularly those that cause businesses to delay or cancel purchase decisions.

CONTACT: For further information, call
         Bonnie Herron, 770-564-5504
         or email to bherron@intelsys.com

SiriusXM’s (SIRI) Not Fade Away Town Hall

SiriusXM’s Town Hall to offer SiriusXM listeners the chance to participate in Q&A with the creator and stars of the “The Sopranos” about the new film “Not Fade Away” in the SiriusXM studios Town Hall to be moderated by Terence Winter, creator of “Boardwalk Empire” and writer for “The Sopranos”

NEW YORK, Dec. 14, 2012 /PRNewswire/ — Sirius XM Radio (NASDAQ: SIRI) announced today that the creator and stars of The Sopranos, David Chase, James Gandolfini and Steven Van Zandt, will sit down for a Q&A session with a select group of SiriusXM listeners about their new film Not Fade Away from Paramount Vantage at the SiriusXM studios in New York City.

(Logo: http://photos.prnewswire.com/prnh/20101014/NY82093LOGO)

“SiriusXM’s Not Fade Away Town Hall” with David Chase, James Gandolfini and Steven Van Zandt, which will take place on Monday, December 17, will air on Underground Garage, channel 21, on Thursday, December 20 at 7:00 pm ET.  For rebroadcast times please visit www.siriusxm.com/townhall.

Moderated by Terence Winter, the Town Hall will feature Not Fade Away’s writer and director David Chase, actor James Gandolfini and the film’s executive producer and musical supervisor Steven Van Zandt answering fan questions about their careers, HBO’s The Sopranos, and their new film, which will be released in theaters nationwide on December 21.

“SiriusXM’s Not Fade Away Town Hall” with David Chase, James Gandolfini, and Steven Van Zandt is part of SiriusXM’s “Town Hall” series featuring intimate gatherings with iconic entertainers and figures sitting down with a studio audience of SiriusXM listeners. Previous SiriusXM “Town Hall” specials have featured Bruce Springsteen, Cardinal Timothy Dolan, Carol Burnett, Tom Petty, KISS, Coldplay, Ringo Starr, Roger Waters, the surviving members of Nirvana, Renee Fleming, Gregg Allman, Usher, Duke basketball coach Mike Krzyzewski and Tony Hawk.

“David, James and Steven worked together to make television history with The Sopranos and now they’ve collaborated on Not Fade Away, a movie whose music will be as interesting as its storyline,” said Scott Greenstein, President and Chief Content Officer, SiriusXM. “We are excited to have them in a rare setting together in our studios in front of lucky fans who can ask them about the effect their work has had on a generation of viewers, and how their new film will expose a new generation to the revolution that transformed pop and rock music in the ’60s.”

After the broadcast, “SiriusXM’s Not Fade Away Town Hall” with David Chase, James Gandolfini and Steven Van Zandt will be available on SiriusXM On Demand for subscribers listening via the SiriusXM Internet Radio App for smartphones and other mobile devices or online at siriusxm.com. Visit www.siriusxm.com/ondemand for more information on SiriusXM On Demand.

For more information on SiriusXM, please visit www.siriusxm.com.

About Sirius XM Radio
Sirius XM Radio Inc. is the world’s largest radio broadcaster measured by revenue and has 23.4 million subscribers.  SiriusXM creates and broadcasts commercial-free music; premier sports talk and live events; comedy; news; exclusive talk and entertainment; and the most comprehensive Latin music, sports and talk programming in radio. SiriusXM is available in vehicles from every major car company in the U.S., from retailers nationwide, and online at siriusxm.com. SiriusXM programming is also available through the SiriusXM Internet Radio App for Android, Apple, and BlackBerry smartphones and other connected devices. SiriusXM also holds a minority interest in SiriusXM Canada which has more than 2 million subscribers.

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning.  Such forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond our control.  Actual results may differ materially from the results anticipated in these forward-looking statements.

The following factors, among others, could cause actual results to differ materially from the anticipated results or other expectations expressed in the forward-looking statements:  our competitive position versus other forms of audio entertainment; our dependence upon automakers; general economic conditions; failure of our satellites, which, in most cases, are not insured; our ability to attract and retain subscribers at a profitable level; royalties we pay for music rights; the unfavorable outcome of pending or future litigation; failure of third parties to perform; and our substantial indebtedness.  Additional factors that could cause our results to differ materially from those described in the forward-looking statements can be found in our Annual Report on Form 10-K for the year ended December 31, 2011, which is filed with the Securities and Exchange Commission (the “SEC”) and available at the SEC’s Internet site (http://www.sec.gov).  The information set forth herein speaks only as of the date hereof, and we disclaim any intention or obligation to update any forward looking statements as a result of developments occurring after the date of this communication.

Follow SiriusXM on Twitter or  like the SiriusXM page on Facebook.

P-SIRI

Media Contact:
Samantha Bowman
SiriusXM
212 901 6644
samantha.bowman@siriusxm.com

LifeVantage (LFVN) Announces Shares Repurchase Program

Company Authorized Repurchase of Up to $5 Million in Shares of Its Common Stock

SALT LAKE CITY, Dec. 14, 2012 (GLOBE NEWSWIRE) — LifeVantage Corporation (Nasdaq:LFVN), a company dedicated to helping people achieve healthy living through a combination of a compelling business opportunity and scientifically validated products, including its patented dietary supplement Protandim^®, the Nrf2 Synergizer^®, announced today that its Board of Directors approved a share repurchase program that authorizes the Company to utilize up to $5 million to purchase shares of its common stock. Any such repurchases will be made out of existing cash or free cash flow from continuing operations.

The repurchase program permits LifeVantage to purchase shares from time to time through a variety of methods, including in the open market, through privately negotiated transactions or other means as determined by the company’s management, in accordance with applicable securities laws. As part of the repurchase program, the Company expects that it will enter into a pre-arranged stock repurchase plan which would operate in accordance with guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934. Accordingly, transactions, if any, under the pre-arranged repurchase plan would be effected in accordance with the terms of the stock repurchase plan, including specified price, volume and timing conditions.

“Given the underlying strength of our business and the recent turbulence in the equity markets, we believe the stock buy-back program is in the best interests of our stockholders,” Douglas C. Robinson, LifeVantage President and CEO, stated. “We intend to implement this buyback program while maintaining sufficient resources to continue to improve our balance sheet and invest in future expansion opportunities.”

The LifeVantage Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=11617

Forward Looking Statements

This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believe,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates” and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not limited to, statements we make regarding our future prospects and our expectation that we will repurchase shares. Such forward-looking statements are not guarantees of performance and the Company’s actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company’s current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company’s actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, the potential failure or unintended negative consequences of the implementation of the Company’s network marketing sales channel; the Company’s ability to retain independent distributors or to attract new independent distributors on an ongoing basis; the potential for third party and governmental actions involving the Company’s network marketing sales channel; the potential for product liability claims against the Company; the risk that government regulators and regulations could adversely affect the Company’s business; future laws or regulations may hinder or prohibit the production or sale of the Company’s existing product and any future products; unfavorable publicity could materially hurt the Company’s business; and the Company’s ability to protect its intellectual property rights and the value of its product. These and other risk factors are discussed in greater detail in the Company’s Annual Report on Form 10-K and its Quarterly Report on Form 10-Q under the caption “Risk Factors,” and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.

CONTACT: Investor Relations Contact:
         Cindy England (801) 432-9036
         Director of Investor Relations
         -or-
         John Mills (310) 954-1105
         Senior Managing Director, ICR, LLC

B.O.S (BOSC) Announces 1-for-4 Reverse Split of Ordinary Shares

RISHON LEZION, Israel, Dec. 14, 2012 (GLOBE NEWSWIRE) — The Company hereby announces that the reverse share split previously announced by the Company on October 31, 2012, shall become effective on December 14, 2012. Pursuant to the reverse split, each 4 Ordinary Shares, NIS 20.00 nominal value per share, will be converted into one Ordinary Share, NIS 80.00 nominal value per share. No fractional shares will be issued as a result of the reverse-split. Instead, all fractional shares will be rounded up to the next higher whole number of shares.

As of December 13, 2012, there were 4,472,298 Ordinary Shares outstanding and after the reverse split there will be 1,118,081 Ordinary Shares outstanding. The exchange agent for the reverse split is American Stock Transfer & Trust Company, whose address is 6201 15^th Avenue, Brooklyn, N.Y. 11219 (tel:  (718) 921- 8317 or (877) 248-6417). Once effective, the post-split shares will trade on the Nasdaq Capital Market under the same symbol “BOSC”.

About BOS

B.O.S. Better Online Solutions Ltd. (Nasdaq:BOSC) is a leading provider of RFID and Supply Chain solutions to global enterprises, that help customers worldwide improve the efficiency of their logistics and organizational monitoring and control. BOS’ RFID and Mobile division offers both turnkey integration services as well as stand-alone products, including best-of-breed RFID and AIDC hardware and communications equipment, BOS middleware, and industry-specific software applications. BOS’ Supply Chain division provides electronic components consolidation services to the aerospace, defense, medical and telecommunications industries.

For more information, please visit:www.boscorporate.com

CONTACT: For more information:
         Eyal Cohen
         CFO
         +972-542525925

U.S. Geothermal’s (HTM) Neal Hot Springs Project Update

BOISE, IDAHO — (Marketwire) — 12/13/12 — U.S. Geothermal Inc. (TSX:GTH)(NYSE MKT:HTM), a leading renewable energy company focused on the development, production and sale of electricity from geothermal energy, provides this update on the Neal Hot Springs project located near Vale, Oregon.

The three module plant is operating and currently delivering 23.0 net megawatts (“MW”) to our customer, Idaho Power Company, with the following status of each module unit:

--  Unit 1 is currently online and operational with gross generation of 11.0
    MW;
--  Unit 2 is also online and operational with gross generation of 10.4 MW;
    and,
--  Unit 3 currently online and was recently synchronized to the grid. Gross
    generation from Unit 3 is 8.7 MW operating in sub critical mode.

The three modules are still undergoing various mechanical and control system adjustments, tests and modifications to meet overall design criteria. The project contractor is expected to complete work during the first quarter of 2013.

Please visit our Website at: www.usgeothermal.com

About U.S. Geothermal Inc.:

U.S. Geothermal Inc. is a leading renewable energy company focused on the development, production and sale of electricity from geothermal energy and is operating geothermal power projects at Raft River, Idaho, San Emidio, Nevada and Neal Hot Springs, Oregon. The company is developing El Ceibillo, an advanced stage, steam geothermal prospect located within a 24,710 acre (100sq km) energy rights concession area located 8.5 miles (14 km) from Guatemala City, the largest city in Central America.

The information provided in this news release may contain forward-looking statements within the definition of the Safe Harbor provisions of the US Private Securities Litigation Reform Act of 1995. These statements are based on U.S. Geothermal Inc.’s current expectations and beliefs and are subject to a number of risks and uncertainties that can cause actual results to differ materially from those described, including but not limited to, the results from the start up activities and ongoing production potential of Neal Hot Springs. Readers are cautioned to review the risk factors identified by the company in its filings with Canadian and US securities agencies. Forward-looking statements are based on management’s expectations, beliefs and opinions on the date the statements are made. U.S. Geothermal Inc. assumes no obligation to update forward-looking statements if management’s expectations, beliefs, or opinions, or other factors, should change.

The NYSE MKT and the TSX do not accept responsibility for the adequacy of this release.

Contacts:
U.S. Geothermal Inc.
Saf Dhillon
Investor Relations
866-687-7059
208-424-1030 (FAX)
saf@usgeothermal.com

SoundBite (SDBT) Announces Special Dividend to Stockholders Payable in December 2012

BEDFORD, Mass., Dec. 13, 2012 (GLOBE NEWSWIRE) — SoundBite Communications (Nasdaq:SDBT), a provider of customer experience management solutions, today announced that its Board of Directors has declared a special, one-time cash dividend of $0.50 per share payable on or before December 31, 2012 to stockholders of record at the close of business on December 23, 2012. The total amount of the special dividend payment will be approximately $8.2 million.

“SoundBite has a solid balance sheet, with approximately $24 million in cash at the end of the third quarter and no long term debt,” said Jim Milton, President and Chief Executive Officer. “We have preserved our cash while funding the acquisition of three mobile companies, executing on a stock buyback program, and investing in transforming the company into a strong position within two growth markets – mobile marketing and the hosted contact center.  SoundBite is on a path towards achieving sustained profitability and has decided to return some of the cash to our stockholders in the form of a fifty-cent dividend.”

Milton continued, “We have made great progress recently in improving our position on the litigation and regulatory front with the favorable declaratory ruling by the FCC on our petition.  Based on our solid positioning in the mobile marketing and hosted contact center markets, we are confident that we can grow organically and will not need this cash for future acquisitions.  We believe that this special dividend will provide stockholders with additional value and appropriately reward them for their continued support.”

SoundBite intends to continue to invest in its mobile marketing and hosted contact center market opportunities, as well as capital expenditures to support platform and infrastructure expansion.

As a result of the special dividend, the exercise prices of some outstanding stock awards will decrease, and the number of shares subject to certain stock awards may increase, pursuant to the existing terms of SoundBite’s equity incentive plan. SoundBite will not be able to determine the extent of those adjustments until early January 2013.

About SoundBite Communications

SoundBite Communications is a customer experience management company with deep expertise in delivering cloud-based mobile marketing, proactive customer care, and collections/payments solutions. More than 450 global end-clients, including nearly 50 Fortune 500 companies, leverage SoundBite’s proactive multi-channel communications and preference management platforms to power 2.5 billion personalized and compliant customer interactions annually across the full consumer lifecycle. Visit SoundBite.com and follow SoundBite on Twitter for more information. SoundBite is a registered service mark of SoundBite Communications, Inc.

The SoundBite Communications, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4393

CONTACT: IR & Media Contact:
         Lynn Ricci
         SoundBite Communications
         781-897-2696
         lricci@soundbite.com
         www.SoundBite.com

Oncolytics (ONCY) Positive Top Line REOLYSIN® Data Head and Neck Cancer

CALGARY, Dec. 13, 2012 /PRNewswire/ – Oncolytics Biotech Inc. (“Oncolytics” or the “Company”) (TSX: ONC) (NASDAQ: ONCY) today announced initial positive top line data from the first endpoint in its double-blinded randomized Phase III clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naïve head and neck cancers (REO 018).

The endpoint examines initial percentage tumour changes between the pre-treatment and first post-treatment scans (typically performed at six weeks post-first treatment) of all patients enrolled in the study. The analysis was designed to assess early differences in response between loco-regional tumours and metastatic tumours, as classified and observed by the investigators. This is the first, and to this point only, endpoint to be un-blinded for this study.

The first analysis compared the relative percentages of patients in the test and control arms with tumours that had either stabilized or exhibited shrinkage. For the purposes of this endpoint, the definition of tumour stabilization was restricted to zero percent growth only. Of the 105 total patients with evaluable metastatic tumours, 86 percent (n=50) of those in the test arm of the study exhibited tumour stabilization or shrinkage, compared with 67 percent of patients (n=55) in the control arm. This was statistically significant, with a p-value of 0.025.

The second analysis examined the magnitude of tumour response on a per patient basis using a comparison of percentage tumour shrinkage at six weeks in each patient with evaluable metastatic tumours. This analysis showed that REOLYSIN in combination with carboplatin and paclitaxel was statistically significantly better than carboplatin and paclitaxel alone at stabilizing or shrinking metastatic tumours, yielding a p-value of 0.03.

At the six week point, there is a numeric trend in favour of the test group towards differing activity between the test and control groups in patients with loco-regional tumours.

In an intragroup analysis of the test arm, an improvement in the percentage of patients’ metastatic tumours over loco-regional tumours was noted (p=0.083) and an improvement of magnitude of response in metastatic tumours over loco-regional tumours was also noted (p=0.13). By contrast, in an intragroup analysis of the control arm, no statistical differences were noted between the responses of patients with evaluable metastatic tumours and patients with evaluable loco-regional tumours.

“To the best of our knowledge, this is the first successful double-blinded randomized data from a clinical study using an intravenously-administered oncolytic virus. We are delighted to have obtained statistically significant data for REOLYSIN in a randomized clinical setting,” said Dr. Brad Thompson, President and CEO of Oncolytics. “We continue to await the data for the other endpoints of this study, to which all parties still remain blinded at this point.”

Conference Call Details
Dr. Brad Thompson, President and CEO of Oncolytics, will host a conference call and webcast on Thursday, December 13^th, 2012 at 6:00 a.m. MT (8:00 a.m. ET) to discuss in more depth the Company’s Phase III study in head and neck cancers. To access the conference call by telephone, dial 1-647-427-7450 or 1-888-231-8191. A live audio webcast will also be available at the following link: http://www.newswire.ca/en/webcast/detail/1087657/1184933 or through the Company’s website at www.oncolyticsbiotech.com/presentations. Please connect at least 10 minutes prior to the webcast to ensure adequate time for any software download that may be needed. A replay of the webcast will be available at www.oncolyticsbiotech.com/presentations and will also be available by telephone through December 20^th, 2012. To access the telephone replay, dial 1-416-849-0833 or 1-855-859-2056 and enter reservation number 81080621 followed by the number sign. The Company also intends to post the prepared remarks from the call to its corporate website following the call.

About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.  Oncolytics’ clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN^®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements within the meaning of the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange Act of 1934, as amended, and forward-looking information within the meaning of Canadian securities laws. Statements, other than statements of historical facts, included in this press release that address activities, events or developments that Oncolytics expects or anticipates will or may occur in the future, including such things as, the Company’s expectations related to the Phase III head and neck cancers trial of REOLYSIN in combination with carboplatin and paclitaxel, and the Company’s belief as to the potential of REOLYSIN as a cancer therapeutic, and other such matters are forward-looking statements and forward-looking information and involve known and unknown risks and uncertainties, which could cause the Company’s actual results to differ materially from those in the forward-looking statements and forward-looking information. Such risks and uncertainties include, among others, risks related to the statistical sufficiency of patient enrollment numbers in separate patient groups, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company’s ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statement and forward-looking information. Investors are cautioned against placing undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update these forward-looking statements and forward-looking information, except as required by applicable laws.

ATC Venture Group (ATC) to Return to the OTC Market

ATC Venture Group Inc. (the “Company”) (NYSE MKT: ATC) announced that it will be returning its listing to the OTC Markets (the”OTC”) from the NYSE MKT (the “Exchange”). The Company’s common stock had previously been traded on the OTC.

The Company expects that the stock will begin trading under a new 4-character ticker symbol on the OTC commencing on Monday, December 17, 2012. Investors will be able to view the Real Time Level II stock quotes for at http://www.otcmarkets.com.

“We believe that the transition to the OTC will provide existing and new shareholders a quality marketplace to trade our stock,” said Robert Davis, Chairman and CEO of the Company. “Furthermore, we believe that the turnaround process that we have been in for the past few years has led to a deeply depressed stock price, and a change to the new market may provide a fresh opportunity for new participants to become aware of us. In addition, there are substantial cost savings to the Company from this change.”

As previously disclosed, on October 5, 2012, the Company received notice from the NYSE MKT indicating that the Company no longer complied with the Exchange’s continued listing standards because the aggregate market value of its public float was less than $1.0 million for 90 consecutive days as set forth in Section 1003(b)(i)(C) of the Exchange’s Company Guide, because it had yet to file its Form 10-Q for the quarter ended June 30, 2012 as set forth in Sections 134 and 1101 of the Company Guide, and because of the low price of the Company’s common stock as set forth in Section 1003(f)(v) of the Company Guide. As a result, the Exchange staff recommended that the Company’s common stock be delisted. The Company appealed their determination.

On December 6, 2012, the Company’s appeal was heard by the Listing Qualifications Panel of the Exchange. On December 10, 2012, the Company received a letter from the Listing Qualifications Panel of the Exchange affirming the staff decision to delist the Company’s common stock.

Mr. Davis said, “After reflecting on the Company’s alternatives to the NYSE MKT, we are confident that our shareholders will be well served by the lower cost platform of the OTC, while we continue to work to create shareholder value. We believe this transition to the OTC will be a positive transition for existing and new shareholders to benefit from their involvement with our business.”

About ATC Venture Group Inc.:

ATC Venture Group is the parent company to Simonsen Iron Works Inc., an Iowa-based fabricator, powder coat painter, and assembler of metal-based products since 1906. It previously owned Cycle Country Accessories, which for over 30 years was the industry leading designer, manufacturer and marketer of snow plows and other accessories for the ATV/UTV Powersports industry, as well as previously owned several other Powersports and Golf industry product businesses.

TORM (TRMD) Regains Compliance With NASDAQ Listing Rules

COPENHAGEN, Denmark, Dec. 12, 2012 (GLOBE NEWSWIRE) — TORM A/S (Nasdaq:TRMD) has received confirmation from NASDAQ Listing Qualifications that the Company’s American Depository Receipts (ADRs) have closed (bid) at USD 1.00 per ADR or greater for ten consecutive trading days. Accordingly, the Company has regained compliance with the NASDAQ Stock Market listing rules.

Contact TORM

A/SJacob Meldgaard, CEO, tel.: +45 3917 9200
Roland M. Andersen, CFO, tel.: +45 3917 9200
C. Soegaard-Christensen, IR, tel.: +45 3076 1288

Tuborg Havnevej 18
DK-2900 Hellerup, Denmark
Tel.: +45 3917 9200 / Fax: +45 3917 9393
www.torm.com

About TORM

TORM is one of the world’s leading carriers of refined oil products as well as a significant player in the dry bulk market. The Company operates a fleet of approximately 110 modern vessels in cooperation with other respected shipping companies sharing TORM’s commitment to safety, environmental responsibility and customer service.
TORM was founded in 1889. The Company conducts business worldwide and is headquartered in Copenhagen, Denmark. TORM’s shares are listed on NASDAQ OMX Copenhagen (ticker: TORM) and on NASDAQ in New York (ticker: TRMD). For further information, please visit www.torm.com.

Safe Harbor statements as to the future

Matters discussed in this release may constitute forward-looking statements and may be more detailed than regular practice. Forward-looking statements reflect our current views with respect to future events and financial performance and may include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and statements other than statements of historical facts. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management’s examination of historical operating trends, data contained in our records and other data available from third parties. Although TORM believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, TORM cannot guarantee that it will achieve or accomplish these expectations, beliefs or projections.
Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward- looking statements include the conclusion of definitive waiver documents with our lenders, the strength of the world economy and currencies, changes in charter hire rates and vessel values, changes in demand for “tonne miles” of oil carried by oil tankers, the effect of changes in OPEC’s petroleum production levels and worldwide oil consumption and storage, changes in demand that may affect attitudes of time charterers to scheduled and unscheduled dry-docking, changes in TORM’s operating expenses, including bunker prices, dry-docking and insurance costs, changes in the regulation of shipping operations, including requirements for double hull tankers or actions taken by regulatory authorities, potential liability from pending or future litigation, domestic and international political conditions, potential disruption of shipping routes due to accidents and political events or acts by terrorists.

Risks and uncertainties are further described in reports filed by TORM with the US Securities and Exchange Commission, including the TORM Annual Report on Form 20-F and its reports on Form 6-K.

Forward-looking statements are based on management’s current evaluation, and TORM is only under an obligation to update and change the listed expectations to the extent required by law.

ACADIA (ACAD) Announces $86 Million Equity Financing

–Proceeds to Support Completion of Pimavanserin Phase III Program–

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced a private placement equity financing pursuant to which ACADIA will receive gross proceeds of $86.4 million from the sale of its securities. Shares of ACADIA’s common stock will be sold at $4.43 per share, the closing market price on December 11, 2012. The private placement is expected to close on December 17, 2012 and is subject to the satisfaction of customary closing conditions.

The anticipated proceeds from the private placement will be used primarily to support completion of ACADIA’s Phase III pimavanserin program, including its planned confirmatory Phase III pivotal trial in Parkinson’s disease psychosis.

Jefferies & Company, Inc. and Cowen and Company, LLC acted as joint lead placement agents; JMP Securities LLC acted as co-placement agent in the transaction.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

The securities being sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. ACADIA has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable in connection with the private placement.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. ACADIA has a pipeline of product candidates led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson’s disease psychosis. ACADIA also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two advanced preclinical programs directed at Parkinson’s disease and other neurological disorders. All product candidates are small molecules that emanate from discoveries made at ACADIA. ACADIA maintains a website at www.acadia-pharm.com to which ACADIA regularly posts copies of its press releases as well as additional information and through which interested parties can subscribe to receive email alerts.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements related to the progress and timing of ACADIA’s drug discovery and development programs, either alone or with a partner, including the progress of clinical trials, and the clinical benefits to be derived from ACADIA’s product candidates, in each case including pimavanserin. In particular, forward-looking statements include statements regarding the expected proceeds from and timing of the closing of the private placement, the use of proceeds from the private placement, including whether the proceeds will be sufficient to fund the completion of the Phase III program for pimavanserin, including the planned confirmatory Phase III pivotal trial, and the anticipated filing of a registration statement to cover resales of common stock issuable in connection with the private placement. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development, regulatory review and commercialization, including in collaborations with others, the fact that past results of clinical trials may not be indicative of future trial results, and ACADIA’s ability to satisfy the conditions to closing the private placement. For a discussion of these and other factors, please refer to ACADIA’s annual report on Form 10-K for the year ended December 31, 2011 as well as ACADIA’s subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

DayStar (DSTI) Announces Former Clinton Admin and NM Governor Bill Richardson Joins Board

DayStar Technologies (DSTI) Announces That Former United States Secretary of Energy and Ambassador to the United Nations Under President Clinton’s Administration and the Former Governor of New Mexico, William (Bill) Richardson, Joins Its Board of Directors

KELOWNA, BC — (Marketwire) — 12/12/12 — DayStar Technologies, Inc. (NASDAQ: DSTI) announces a new member to their Board of Directors. Former United States Secretary of Energy, former Governor of New Mexico and Nobel Prize nominee, Bill Richardson, has joined the Board of Directors of DayStar Technologies.

Lorne (Mark) Roseborough, President of DayStar, stated, “Bill Richardson made New Mexico the ‘Clean Energy State’ by requiring utilities to meet 20% of New Mexico’s electrical demand from renewable sources, and established the Renewable Energy Transmission Authority to deliver New Mexico’s world-class renewable resources to market. This level of determination matches DayStar’s commitment in the Global Renewable Energy Industry. Mr. Richardson’s international respect and recognition in this industry will bring proven leadership in assisting DayStar’s execution of its global business model.”

Prior to being elected governor, Mr. Richardson served for 15 years in New Mexico representing the 3rd Congressional District. In 1997 &1998 Mr. Richardson served as the U.S. Ambassador to the United Nations, and he was unanimously confirmed by the U.S. Senate as Secretary of the U.S. Department of Energy under the Clinton Administration.

Daniel Germain, Chairman of the Nomination Committee and founder of the Breakfast Clubs of Canada, stated, “Mr. Richardson, and his diplomatic skills honed through years of public and private service, will complement DayStar’s local, national and international presence. One of the reasons he held the positions of Governor, U.S. Secretary of Energy, and United Nations Ambassador is because of his level of dedication to protecting the rights and improving the quality of life for people everywhere.”

Since leaving his public service office, Mr. Richardson was named chairman of APCO Worldwide’s executive advisory service Global Political Strategies (GPS) and Special Envoy for the Organization of American States (OAS), adding another platform for initiatives within peace and reconciliation in the Western hemisphere. In addition, Mr.Richardson serves as Senior Fellow for Latin America at Rice University’s James A. Baker III Institute for Public Policy and has joined several non-profit and for-profit boards, including Abengoa’s International Advisory Board, the fifth largest biofuels producer in the U.S., WRI World Resources Institute, Refugees International and the National Council for Science and the Environment.

About DayStar Technologies, Inc:

DayStar Technologies, Inc. (DSTI) is a developer of solar photovoltaic products based upon CIGS thin film deposition technology and is currently embarked on a strategy of strategic partnerships to enter new markets within the global renewal energy industry including ownership and construction of solar and renewable power plants. For more information, visit the DayStar website at http://www.daystartech.com/.

For further information contact, William J. Nalley, Orsay Groupe, 305-515-8077, Info@orsaygroupe.com.

Safe Harbor: Statements contained in this news release which are not historical facts may be forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. They often include words like “believe,” “expect,” “anticipate,” “estimate” and “intend” or future or conditional verbs such as “will,” “would,” “should,” “could” or “may.” We undertake no obligation to update any forward-looking statements.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
William Nalley
Orsay Groupe, Inc.

Gilead Sciences to Acquire YM BioSciences (YMI)

– Adds Selective JAK Inhibitor to Growing Oncology and Inflammation Pipeline –

Gilead Sciences, Inc. (Nasdaq: GILD) and YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) announced today that the companies have signed a definitive agreement under which Gilead will acquire YM for U.S.$2.95 per share in cash. The transaction has received the unanimous approval of YM’s Board of Directors, and values YM at approximately U.S.$510 million, with YM reporting C$125.5 million in cash and cash equivalents as of September 30, 2012. Gilead plans to fund the acquisition with cash on hand. The transaction is expected to close in the first quarter of 2013.

YM’s lead drug candidate, CYT387, is an orally-administered, once-daily, selective inhibitor of the Janus kinase (JAK) family, specifically JAK1 and JAK2. The JAK enzymes have been implicated in a number of disorders including myeloproliferative diseases, inflammatory disorders and certain cancers. YM has reported positive results from a Phase 1/2 clinical trial of CYT387 in 166 patients with myelofibrosis, a life-threatening myeloproliferative disease. Pending completion of the acquisition, Gilead intends to initiate a pivotal Phase 3 clinical trial of CYT387 in myelofibrosis in the second half of 2013.

“This acquisition represents an opportunity to add a complementary clinical program in the area of hematologic cancers to our growing oncology portfolio,” said Norbert W. Bischofberger, PhD, Gilead’s Executive Vice President, Research and Development and Chief Scientific Officer. “Based on promising Phase 2 data, we believe CYT387 could provide important clinical benefit for patients with myelofibrosis, including potential improvements with regard to anemia and decreased dependence on blood transfusions. We look forward to advancing CYT387 into a Phase 3 study as quickly as possible and to exploring its potential in other myeloproliferative diseases with significant unmet medical need.”

Myelofibrosis is a progressive, chronic bone marrow disorder in which the marrow is replaced by fibrous scar tissue, making it difficult for the bone marrow to sufficiently produce blood cells, leading to anemia (low red blood cell count) and thrombocytopenia (low blood platelet count), severe constitutional symptoms and spleen enlargement. JAK inhibitors modulate cytokine-stimulated intracellular signalling and decrease the circulating levels of proinflammatory cytokines associated with the pathogenesis of myelofibrosis.

“This agreement represents a positive outcome both for myelofibrosis patients and for our shareholders. Gilead has the research and development capabilities and the resources needed to more fully realize the potential of CYT387 as a therapeutic advance for myelofibrosis patients and potentially for other indications,” said Dr. Nick Glover, President and CEO of YM.

“Since our acquisition of CYT387 nearly three years ago, YM has made great progress in advancing CYT387 through the clinical, regulatory, manufacturing and business development processes. While Gilead’s acquisition will end a long, varied and interesting journey for YM, we are pleased to have this transaction crystallize the present value of this important therapeutic candidate,” said Mr. David Allan, Chairman of YM.

In recent years, Gilead has sought to expand its R&D expertise in the area of oncology through the appointment of leading cancer researchers and clinicians, the establishment of external scientific partnerships and through strategic acquisitions. Gilead’s lead compound in oncology, idelalisib (formerly referred to as GS-1101), is an investigational, first-in-class specific inhibitor of the phosphoinositide-3 kinase (PI3K) delta isoform. Five Phase 3 studies of idelalisib in chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin’s lymphoma (iNHL) are progressing.

Gilead is also conducting Phase 2 clinical trials of simtuzumab (formerly referred to as GS-6624), an investigational monoclonal antibody (mAb) candidate targeting the human lysyl oxidase-like 2 (LOXL2) protein, in myelofibrosis, colorectal cancer, pancreatic cancer and certain fibrotic diseases.

CYT387, idelalisib and simtuzumab are investigational products and their safety and efficacy have not yet been established.

Terms of the Transaction

Under the terms of the agreement, upon closing of the proposed transaction, shareholders of YM will receive U.S.$2.95 per common share in cash, and holders of warrants and stock options will receive a cash payment equal to the difference between U.S.$2.95 and the exercise price of such warrant or stock option. The proposed transaction will be completed through a plan of arrangement under the provisions of the Companies Act (Nova Scotia).

The transaction will require the approval of YM shareholders at a special meeting of YM shareholders, to be held as soon as reasonably practicable and in any event on or before February 11, 2013. In addition to YM’s shareholder approval, closing of the transaction is subject to the satisfaction of certain other customary conditions, including court approval of the transaction, and applicable government and regulatory approvals, including expiration or termination of the waiting period under the United States Hart Scott Rodino Antitrust Improvements Act, and the review period under the Competition Act (Canada). The approval of Gilead shareholders is not required in connection with the proposed transaction.

The arrangement agreement contains customary non-solicitation provisions, but permits YM, in certain circumstances, to terminate the arrangement and accept an unsolicited superior proposal, subject to fulfilling certain conditions.

BofA Merrill Lynch and Bloom Burton & Co. serve as financial advisors, and Gowling Lafleur Henderson LLP, Heenan Blaikie LLP and Dorsey & Whitney LLP serve as legal advisors to YM in connection with the transaction. Gilead is advised by Wilson Sonsini Goodrich & Rosati, Professional Corporation and Blake Cassels and Graydon LLP.

About YM

YM BioSciences Inc. is a drug development company primarily focused on advancing CYT387, an orally administered inhibitor of both the JAK1 and JAK2 kinases, which have been implicated in a number of hematological and immune cell disorders including myeloproliferative neoplasms and inflammatory diseases as well as certain cancers. Positive interim results have been reported from a Phase 1/2 trial of CYT387 in 166 patients with myelofibrosis. In addition, YM has several preclinical programs underway with candidates from its library of novel compounds identified through internal research conducted at YM BioSciences Australia.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.

YM Forward-Looking Statement

This press release may contain forward-looking statements, which reflect YM’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, shareholder approval of the proposed Arrangement; YM’s ability to obtain court, regulatory, and other approvals in connection with the proposed Arrangement; uncertainties as to the timing of the Arrangement; the satisfaction of the conditions precedent to the completion of the Arrangement, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the Arrangement; changing market conditions; the successful and timely completion of clinical studies; the establishment of corporate alliances; the impact of competitive products and pricing; new product development; uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in YM’s ongoing quarterly and annual reporting. Except as required by applicable securities laws, YM undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Gilead Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of the companies’ and members of their senior management team. Forward-looking statements include, without limitation, the ability of Gilead to advance YM’s product pipeline, including CYT387, the possibility that Gilead will be unable to initiate a Phase 3 trial of CYT387 in myelofibrosis as currently anticipated; the possibility of unfavorable results of clinical trials of CYT387, idelalisib and simtuzumab; the expected timing of the completion of the transaction; and the ability to complete the transaction considering the various closing conditions, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: the effects of the transaction on relationships with employees, customers, other business partners or governmental entities; other business effects, including the effects of industry, economic or political conditions outside of the companies’ control; actual or contingent liabilities; and other risks and uncertainties detailed from time to time in Gilead’s Report on Form 10-Q and for the quarter ended September 30, 2012. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Additional Information and Where to Find It

Further information regarding the transaction will be contained in an information circular that YM will prepare and mail to its shareholders in connection with the YM shareholders’ meeting, with closing expected to occur in the first quarter of 2013. YM shareholders are urged to read the information circular once it becomes available, as it will contain important information concerning the proposed transaction. YM shareholders may obtain a copy of the arrangement agreement, information circular, and other meeting materials when they become available at www.sec.gov and www.sedar.com.

This press release is for informational purposes only. It does not constitute an offer to purchase shares of YM or a solicitation or recommendation statement under the rules and regulations of the United States Securities and Exchange Commission or other applicable laws.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com,

follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5

or 1-650-574-3000.

For more information on YM BioSciences, please visit the company’s website at www.ymbiosciences.com or contact James Smith, VP Corporate Affairs at 905.361.9518 or jsmith@ymbiosciences.com